U.S. patent application number 12/051397 was filed with the patent office on 2008-09-18 for subunit vaccine against respiratory syncytial virus infection.
This patent application is currently assigned to ID Biomedical Corporation of Quebec. Invention is credited to Robert ANDERSON, David S. BURT, Yan HUANG.
Application Number | 20080226673 12/051397 |
Document ID | / |
Family ID | 34084525 |
Filed Date | 2008-09-18 |
United States Patent
Application |
20080226673 |
Kind Code |
A1 |
ANDERSON; Robert ; et
al. |
September 18, 2008 |
SUBUNIT VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTION
Abstract
The present invention relates generally to methods of treating
or preventing RSV infections, and more specifically, to
compositions, and the use thereof, comprising one or more RSV G
protein immunogen or fragment thereof capable of eliciting
protective immunity without eliciting an immunopathological
response or eliciting a reduced immunopathological response.
Inventors: |
ANDERSON; Robert; (US)
; HUANG; Yan; (US) ; BURT; David S.;
(US) |
Correspondence
Address: |
GLAXOSMITHKLINE;Corporated Intellectual Property - UW2220
P.O. Box 1539
King of Prussia
PA
19406-0939
US
|
Assignee: |
ID Biomedical Corporation of
Quebec
|
Family ID: |
34084525 |
Appl. No.: |
12/051397 |
Filed: |
March 19, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10888805 |
Jul 9, 2004 |
7368537 |
|
|
12051397 |
|
|
|
|
60487804 |
Jul 15, 2003 |
|
|
|
60567586 |
May 3, 2004 |
|
|
|
Current U.S.
Class: |
424/204.1 ;
435/183; 530/324 |
Current CPC
Class: |
A61K 2039/55555
20130101; C12N 2760/18522 20130101; C07K 14/005 20130101; A61K
39/155 20130101; A61K 39/12 20130101; A61P 31/14 20180101; C12N
2760/18534 20130101; A61K 2039/55572 20130101; A61K 2039/543
20130101; A61P 11/06 20180101; A61K 2039/55505 20130101; A61P 37/00
20180101; A61K 2039/55594 20130101; A61P 43/00 20180101; A61K
2039/55588 20130101 |
Class at
Publication: |
424/204.1 ;
530/324; 435/183 |
International
Class: |
A61K 39/00 20060101
A61K039/00; C07K 14/00 20060101 C07K014/00; A61P 37/00 20060101
A61P037/00; C12N 9/00 20060101 C12N009/00 |
Claims
1. A respiratory syncytial virus (RSV) G protein comprising an
alanine at the position corresponding amino acid position 191 of
SEQ ID NO:2 or a fragment thereof comprising an epitope that
elicits a protective immune response, wherein the fragment
comprises amino acids corresponding to positions from about amino
acid position 165 to about amino acid position 195 of SEQ ID
NO:2.
2. The RSV G protein polypeptide of claim 1, wherein the
polypeptide comprises from amino acid 165 to amino acid 195 of SEQ
ID NO:2.
3. The RSV G protein polypeptide of claim 1, wherein the fragment
comprises SEQ ID NO:6.
4. The RSV G protein polypeptide of claim 1, wherein said G protein
polypeptide further comprises a hydrophobic moiety.
5. The RSV G protein polypeptide of claim 4, wherein the
hydrophobic moiety comprises an amino acid sequence.
6. The RSV G protein polypeptide of claim 4, wherein the
hydrophobic portion is a lipid.
7. The RSV G protein polypeptide of claim 4, wherein the
hydrophobic moiety is at the amino-terminus of the G protein
polypeptide.
8. The RSV G protein polypeptide of claim 4, wherein the
hydrophobic moiety is at the carboxy-terminus of the G protein
immunogen.
9. The RSV G protein polypeptide of claim 1, wherein the G protein
polypeptide further comprises a second amino acid sequence to form
a fusion protein.
10. The RSV G protein polypeptide of claim 9, wherein the second
amino acid sequence comprises a tag or an enzyme.
11. The RSV G protein polypeptide of claim 9, wherein the second
amino acid sequence comprises thioredoxin, polyhistidine, or a
combination thereof.
12. The RSV G protein polypeptide of claim 9, wherein the fusion
protein further comprises a hydrophobic moiety.
13. The RSV G protein polypeptide of claim 12, wherein the
hydrophobic moiety is at the amino-terminus of the fusion
protein.
14. The RSV G protein polypeptide of claim 12, wherein the
hydrophobic moiety is at the carboxy-terminus of the fusion
protein.
15. A method of eliciting a protective immune response against
respiratory syncytial virus (RSV) without eliciting an
immunopathological response or eliciting a reduced
immunopatholgical response comprising administering an effective
amount of a composition comprising the RSV G protein polypeptide of
claim 1.
16. The method of claim 15, wherein the composition comprising the
RSV G protein polypeptide further comprises an adjuvant.
17. The method of claim 16, wherein the composition further
comprises an RSV F protein immunogen.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of application Ser. No.
10/888,805 filed Jul. 9, 2004, which is incorporated herein by
reference. This application also claims the benefit of U.S.
Provisional Patent Application No. 60/567,586, filed May 3, 2004;
and U.S. Provisional Patent Application No. 60/487,804, filed Jul.
15, 2003, in which these provisional applications are incorporated
herein by reference in their entireties.
TECHNICAL FIELD
[0002] The present invention relates generally to the prevention of
infectious disease, and more specifically, to compositions, and the
use thereof, comprising one or more respiratory syncytial virus G
protein immunogens and fragments or variants thereof capable of
eliciting protective immunity without eliciting an
immunopathological response or with a reduced immunopathological
response (e.g., reducing associated pulmonary pathology).
BACKGROUND
[0003] Respiratory syncytial virus (RSV) is the leading cause of
lower respiratory tract infection (acute bronchiolitis and
pneumonia) in early infancy (Glezen et al., Amer. J. Dis. Child.
140:543, 1986; Holberg et al., Am. J. Epidemiol. 133:1135, 1991;
"Fields Virology", Fields, B. N. et al. Raven Press, N.Y. (1996),
particularly, Chapter 44, pp 1313-1351 "Respiratory Syncytial
Virus" by Collins, P., McIntosh, K., and Chanock, R. M.). Virtually
all children are infected with RSV by the age of two years and 1-2%
of all infected children require hospitalization (Holberg et al.;
Parrott et al., Am. J. Epidemiol. 98:289, 1973). Outbreaks of RSV
infection and lower respiratory tract deaths in infants and young
children show a strong correlation (Anderson et al., J. Infect.
Dis. 161:640, 1990), and mortality rates among hospitalized
children range between 0.1-1% in the U.S. and Canada (Holberg et
al.; Parrott et al.; Navas et al., J. Pediatr. 121:348, 1992; Law
et al., Pediatr. Infect. Dis. J 12:659, 1993; Ruuskanen and Ogra,
Curr. Prob. Pediatr. 23:50, 1993). The consequences of RSV
infection during infancy range from bronchiolitis or pneumonia to
an increased risk for childhood asthma.
[0004] Despite intense efforts spanning the past four decades, the
search for a safe and effective vaccine against RSV remains
elusive. Initial RSV vaccines, including formalin-inactivated and
live attenuated virus (reviewed in Murphy et al., Virus Res. 32:13,
1994), proved to be disappointingly non-protective and actually led
to more severe lung disease in vaccinated children who subsequently
acquired natural RSV infection. Immunopathological responses,
especially involving inflammatory cell infiltration, may likely
underlie RSV-mediated damage to lung tissue. Children who received
the formalin-inactivated RSV vaccine developed high levels of
virus-specific antibodies, but the antibodies had low levels of
neutralizing activity (Murphy et al., J. Clin. Microbiol. 24:197,
1986) and failed to protect against infection by RSV (Kim et al.,
Am. J. Epidemiol. 89:422, 1969; Kapikian et al., Am. J. Epidemiol.
89:405, 1969; Fulginiti et al., Am. J. Epidemiol. 89:435, 1969;
Chin et al., Virol. 1:1, 1969).
[0005] More recent efforts for development of an RSV vaccine have
focused on subunit and recombinant methods. RSV has two major
surface glycoproteins (designated F and G), which have been
examined for use in potential vaccines. The F protein is involved
in membrane fusion between the virus and target cell (Walsh and
Hruska, J. Virol. 47:171, 1983), whereas the G protein is thought
to mediate attachment of the virus to a cell receptor (Levine et
al., J. Gen. Virol. 68:2521, 1987). Both RSV F and G proteins
induce strong serum and mucosal immunity, which are important for
protection against RSV infection (Glezen et al., 1986; Holberg et
al.; Glezen et al., J. Pediatr. 98:708, 1981; Lamprecht et al., J.
Infect. Dis. 134:211, 1976; Hemming et al., Clin. Microbiol. Rev.
8:22, 1995). Studies with mice have demonstrated that
formalin-inactivated RSV and some G protein-encoding vaccinia
recombinants prime for a harmful lung inflammatory response in
which eosinophils are a prominent participant (Connors et al., J.
Virol. 68:5321, 1994; Doherty, Trends Microbiol. 2:148, 1994; Waris
et al., J. Virol. 70:2852, 1996; Graham et al., J Immunol.
151:2032, 1993; Beasley et al., Thorax 43:679, 1988; Openshaw et
al., Int. Immunol. 4:493, 1992).
[0006] Eosinophils and the eosinophil-attractant cytokine IL-5 are
considered to be a feature of the so-called type 2 immune response,
which has fostered the idea that immunization with RSV antigen has
the potential to trigger type 2 responses depending on factors,
such as the nature of specific viral immunogens and their route of
presentation (Openshaw et al., 1992; Kakuk et al., J. Infect. Dis.
167:553, 1993; Openshaw and O'Donnell, Thorax 49:101, 1994). Recent
work indicates that a portion of the conserved region of the RSV G
protein is involved in protective immunity against RSV and in the
generation of inflammatory responses, including the induction of
eosinophilia (Sparer et al., J. Expt'l. Med. 187:1921, 1998; Tebbey
et al., J. Expt'l. Med 188:1967, 1998; Srikiatchachom et al., J.
Virol. 73:6590, 1999; Varga et al., J. Immunol. 165:6487, 2000;
Huang and Anderson, Vaccine 21:2500, 2003).
[0007] Hence, a need exists for identifying and developing
compositions therapeutically effective against RSV infections,
particularly those compositions that can function as a vaccine by
eliciting protective immunity without any or with a reduced
associated harmful pulmonary inflammation. Furthermore, there is a
need for vaccine formulations that can be varied to protect against
or treat for infection by different RSV immunogenic subtypes and
subgroups. The present invention meets such needs, and further
provides other related advantages.
BRIEF SUMMARY OF THE DISCLOSURE
[0008] The present invention provides the discovery of therapeutic
formulations of respiratory syncytial virus (RSV) immunogens,
particularly G protein immunogens useful for eliciting a protective
immune response without eliciting an, or with a reduced,
immunopathological response.
[0009] In one aspect, the invention provides a method for treating
or preventing an RSV infection, comprising administering to a
subject in need thereof a composition comprising at least one
respiratory syncytial virus G protein immunogen or fragment thereof
comprising an amino acid sequence that is at least 80% identical to
SEQ ID NO:2, wherein said G protein immunogen has an epitope that
elicits a protective immune response without eliciting an, or with
a reduced, immunopathological response, and a pharmaceutically
acceptable carrier, diluent, or excipient, at a dose sufficient to
elicit an immune response specific for one or more G protein
immunogen or fragments and variants thereof. In a related
embodiment, the G protein immunogen is an amino acid sequence
comprising or consisting of SEQ ID NO:2. In other embodiments, the
invention provides a method for treating or preventing a
respiratory syncytial virus infection wherein the G protein
immunogen comprises an amino acid sequence selected from SEQ ID
NOS:6, 8, 10, 12, 14, 16, 18, 20, 22, 56, 58, 60, 62, 64, 66, 68 or
70. In still more embodiments, the invention provides a method
wherein the composition further comprises at least one respiratory
syncytial virus F protein immunogen or M protein immunogen, wherein
the F protein and M protein immunogens have an epitope that elicits
a protective immune response without eliciting an, or with a
reduced, immunopathological response, or has at least two G protein
immunogens.
[0010] In another embodiment, any of the aforementioned G protein
immunogens and fragments or variants thereof further comprise a
hydrophobic portion or moiety (e.g., to act as an anchor or foot in
a lipid environment such as a membrane or proteosome or liposome),
particularly when formulated with a proteosome adjuvant delivery
vehicle. In yet other embodiments, the hydrophobic moiety comprises
an amino acid sequence or a lipid. In certain embodiments, the
carrier is a liposome, and in other embodiments the liposome
contains Deinococcus radiodurans lipids or
.alpha.-galactosylphosphotidylglycerol alkylamine. In another
embodiment, any of the aforementioned compositions further comprise
an adjuvant, such as alum, Freund's adjuvant, or a proteosome-based
formulation (e.g., a proteosome adjuvant delivery system).
Preferably, the adjuvant is suitable for use in humans. In other
embodiments, the G protein immunogen or fragment and variants
thereof further comprise a second amino acid sequence to form a
fusion protein, wherein the second amino acid sequence can be a
tag, an enzyme or a combination thereof, such as a polyhistidine,
thioredoxin, or both. In certain embodiments, such fusion proteins
may further comprise a hydrophobic moiety. In yet other
embodiments, any of the aforementioned methods are provided for use
when the immunopathological response resulting from or associated
with RSV infection is eosinophilia (such as pulmonary eosinophilia)
or asthma. In still more embodiments, the invention provides any of
the aforementioned methods for use when the infection is due to an
RSV of subgroup A, subgroup B, or both subgroup A and subgroup B.
In related embodiments, any of the disclosed compositions may be
administered in any of the aforementioned methods by a route
selected from enteral, parenteral, transdermal, transmucosal, nasal
or inhalation.
[0011] In another aspect, the invention provides a plurality of
antibodies, Th cells, or both produced by a method according to any
one of aforementioned methods. In one embodiment, there is provided
a method for treating or preventing an RSV infection, comprising
administering to a subject in need thereof a composition comprising
a pharmaceutically acceptable carrier or a proteosome adjuvant
delivery vehicle, and a plurality of antibodies as just
described.
[0012] In still another aspect, there is provided a composition
comprising a respiratory syncytial virus G protein immunogen
formulated with a proteosome adjuvant delivery vehicle, wherein
said G protein immunogen comprises an amino acid sequence that is
at least 80% identical to SEQ ID NO:2 or fragment thereof and
wherein said G protein immunogen or fragment thereof has an epitope
that elicits a protective immune response without eliciting an
immunopathological response or with a reduced immunopathological
response. In other embodiments, the composition includes any of the
aforementioned G protein immunogens and fragments or variants
thereof, fusion proteins, multivalent fusions, cocktail
compositions or any combination thereof, and other additives, such
as an adjuvant. In some embodiments, the adjuvant is alum,
proteosome or protollin.
[0013] These and other aspects of the present invention will become
evident upon reference to the following detailed description and
attached drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0014] FIG. 1 shows the induction of serum antibodies in mice
immunized with wild type or mutant Trx-(polyHis)-G(128-229)
proteins in alum and their ability to recognize wild type RSV G
protein and the effect of G protein mutations on such induction.
Extracts of RSV-infected HEp-2 cells were resolved by SDS-PAGE,
transferred to membranes, and probed with pooled sera from each
group of mice (mice were immunized twice at 14-day intervals with
PBS/alum, or alum-adjuvanted wild type or mutant
Trx-(polyHis)-G(128-229) proteins). Shown is an immunoblot of an
SDS-PAGE gel illustrating the specificity of mouse sera (1:100
dilution) for the RSV G protein.
[0015] FIGS. 2A and 2B show how G protein variants affect
protective immunity (A) and eosinophilic infiltration in
bronchoalveolar fluids (B) in immunized mice challenged with RSV.
Mice were immunized twice subcutaneously at 14-day intervals with
PBS/alum or wild type or mutant Trx-G128-229 proteins in alum,
followed by RSV challenge. RSV titers in lung homogenates, as well
as bronchoalveolar lavage eosinophils (as % of total cells) were
determined four days after RSV challenge. Results are shown as
means .+-.SD.
[0016] FIGS. 3A and 3B show the nucleic acid sequence (SEQ ID NO:1)
and amino acid sequence (SEQ ID NO:2) of RSV group A, Long strain G
protein. Shown in bold is an exemplary mutation of an amino acid
(N191A, from codon AAC to GCC) to generate a G protein immunogen of
the invention, from which fragments and variants thereof can be
used as described herein.
[0017] FIGS. 4A and 4B show polyacrylamide gel autoradiograms of
ribonuclease protection assays (RPAs) of cytokine mRNA in lung
tissue. The results illustrate relative levels of cytokine mRNA in
lungs of mice assayed four days after RSV challenge, having been
previously immunized twice subcutaneously at 14-day intervals with
PBS/alum alone, alum-adjuvanted wild type Trx-G128-229 protein, or
variant Trx-G128-229 proteins. Panels A and B show different
regions of the polyacrylamide gel that exposed radiographic film
for 3 days (A) or 1 hour (B).
[0018] FIG. 5 shows the detection by ELISA of specific serum IgG
antibodies from BALB/c mice immunized with wild type or mutant
Trx-(polyHis)-G(128-229) fusion proteins alone, or adjuvanted with
protollin or alum. Mice were immunized three times with a dose of 6
.mu.g or 2 .mu.g of Trx-(polyHis)-G(128-229) fusion proteins.
Protollin alone or fusion proteins formulated with protollin were
administered intranasally, and alum alone or fusion proteins
formulated with alum were administered subcutaneously. Serum
samples were obtained after the second immunization (day 35) and
two weeks after the third immunization (day 62).
[0019] FIG. 6 shows the detection by ELISA of specific
bronchoalveolar lavage (BAL) IgA antibodies from BALB/c mice
immunized with wild type or mutant Trx-(polyHis)-G(128-229) fusion
proteins alone, or adjuvanted with protollin or alum. Mice were
immunized three times with a dose of 6 .mu.g or 2 .mu.g of
Trx-(polyHis)-G(128-229) fusion proteins. Protollin alone or fusion
proteins formulated with protollin were administered intranasally,
and alum alone or fusion proteins formulated with alum were
administered subcutaneously. BAL samples were collected on day 62
(two weeks after the third immunization).
DETAILED DESCRIPTION
[0020] As set forth above, the present invention provides
compositions and methods for using and making respiratory syncytial
virus (RSV) G protein immunogen to treat or prevent respiratory
syncytial virus infection. Although protection against RSV
re-infection (i.e., challenge) could be obtained with previous
vaccines consisting of various forms and immunization modes of the
RSV G protein, this was often associated with an unwanted and
harmful pulmonary inflammation characterized by pronounced
eosinophilia. In addition, immunization of subjects prone to
serious RSV disease (e.g., human subjects between the ages of 2 and
7 months of age) may be difficult due to possible immunosuppressive
effects of maternally derived serum RSV-neutralizing antibodies or
because of the immunological immaturity of the subject. The instant
invention, therefore, relates generally to the surprising discovery
that certain RSV G protein fragments can be modified to induce or
elicit protective immunity against RSV and not induce or have a
reduced level of a concomitant immunopathological event that leads
to, for example, pulmonary inflammation and aggravated disease upon
subsequent infection with RSV. In particular, these G protein
immunogens are useful for treating or preventing infections
involving RSV. Discussed in more detail below are G protein
immunogens or fragments and variants thereof suitable for use
within the present invention, as well as representative
compositions and therapeutic uses.
[0021] In the present description, any concentration range,
percentage range, ratio range or integer range is to be understood
to include the value of any integer within the recited range and,
when appropriate, fractions thereof (such as one tenth and one
hundredth of an integer), unless otherwise indicated. As used
herein, "about" or "comprising essentially of" mean .+-.15%. The
use of the alternative (e.g., "or") should be understood to mean
either one, both or any combination thereof of the alternatives. In
addition, it should be understood that the individual compounds, or
groups of compounds, derived from the various combinations of the
sequences, structures, and substituents described herein, are
disclosed by the present application to the same extent as if each
compound or group of compounds was set forth individually. Thus,
selection of particular sequences, structures, or substituents is
within the scope of the present invention.
RSV G Protein Immunogens
[0022] The present invention is directed generally to immunogenic
RSV polypeptide immunogens of G protein or fragments and variants
thereof, including fusions to other polypeptides (e.g., a tag,
another protein, a hydrophobic amino acid sequence, or any
combination thereof) or other modifications (e.g., addition of a
lipid or glycosylation). The immunogenic G polypeptides may
comprise any portion or fragment of a G protein that has an epitope
capable of eliciting a protective immune response against RSV
infection without eliciting an immunopathological response or with
a reduced immunopathological response. Immunogenic polypeptides of
the instant invention may be arranged or combined in a linear form,
and each immunogen may or may not be reiterated, wherein the
reiteration may occur once or multiple times. In addition, a
plurality of different RSV immunogenic polypeptides (e.g.,
different G protein, F protein, or M protein variants and fragments
or variants thereof) can be selected and mixed or combined into a
cocktail composition or fused, conjugated or linked to provide a
multivalent vaccine for use in eliciting a protective immune
response without a harmful associated immune response.
[0023] As used herein, "G protein immunogen" or "RSV immunogen"
refers to all full length polypeptides, full length variants,
fragments and variants thereof, multivalent fusions, cocktail
compositions, fusion proteins, or any combination thereof, capable
of eliciting a protective immune response against RSV infection
without eliciting an immunopathological response or with a reduced
immunopathological response, as described herein.
[0024] The present invention further provides methods for producing
synthetic or recombinant multivalent RSV polypeptide immunogens,
including fusion proteins. For example, host cells containing G
protein immunogen-encoding nucleic acid expression constructs may
be cultured to produce recombinant G protein immunogens and
fragments or variants thereof. Also contemplated are methods for
treating or preventing RSV infections or eliciting an immune
response using a G protein immunogens and fragments or variants
thereof, or a combination of polypeptides (including fusion
proteins).
[0025] As used herein, the phrase "immunopathological response"
refers to a condition or disease resulting from an immune reaction,
which may or may not have detectable clinical symptoms. Exemplary
immunopathological responses include hypersensitivity or asthma.
Another exemplary immunopathological response can be an atypical
induction of granulocytes in response to type 2 cytokines, such as
is found in blood eosinophilia or pulmonary eosinophilia, which can
be characteristic of an allergic state or a microbial infection
(such as a parasitic infection or a respiratory syncytial virus
infection).
[0026] By way of background and not wishing to be bound by theory,
RSV has a negative-sense, non-segmented, single-stranded RNA
genome, which encodes at least 10 viral proteins (G, F, SH, M, M2,
N, P, L, NS1, and NS2). RSV has two major surface glycoproteins
(designated F and G), which have been examined for use in potential
vaccines. The F protein is involved in membrane fusion between the
virus and target cell (Walsh and Hruska, J. Virol. 47:171, 1983),
whereas the G protein is thought to mediate attachment of the virus
to a cell receptor (Levine et al., J. Gen. Virol. 68:2521, 1987).
Both RSV F and G proteins induce strong serum and mucosal immunity,
which are important for protection against RSV infection (Glezen et
al., 1986; Holberg et al.; Glezen et al., J. Pediatr. 98:708, 1981;
Lamprecht et al., J. Infect. Dis. 134:211, 1976; Hemming et al.,
Clin. Microbiol. Rev. 8:22, 1995). Studies with mice have
demonstrated that formalin-inactivated RSV and some G
protein-encoding vaccinia recombinants prime for a harmful lung
inflammatory response in which eosinophils are a prominent
participant (Connors et al., J. Virol. 68:5321, 1994; Doherty,
Trends Microbiol. 2:148, 1994; Waris et al., J. Virol. 70:2852,
1996; Graham et al., J. Immunol. 151:2032, 1993; Beasley et al.,
Thorax 43:679, 1988; Openshaw et al., Int. Immunol. 4:493, 1992). A
surprising result of the instant invention is the identification of
G protein immunogens (e.g., variants and mutants of wild-type G
protein; an exemplary wild-type G protein is set forth in SEQ ID
NO:4, which can be encoded by a nucleic acid sequence as set forth
in SEQ ID NO:3) that elicit a protective immune response without
eliciting an, or with a reduced, immunopathological response. Thus,
in certain embodiments of the instant invention, a respiratory
syncytial virus G protein immunogen or fragment thereof that has an
epitope that elicits a protective immune response without eliciting
an, or with a reduced, immunopathological response is used to
prepare compositions useful for treating or preventing RSV
infections.
[0027] In certain embodiments, the RSV G protein immunogens have at
least 50% to 100% amino acid identity to an amino acid sequence of
the full length G protein mutant as set forth in SEQ ID NO:2 (from
RSV Group A, Long strain; SEQ ID NO:1 is the nucleic acid sequence
that encodes amino acid sequence of SEQ ID NO:2), or fragments
thereof as set forth in SEQ ID NOS:6, 8, 10, 12, 14, 16, 18, 20,
22, 56, 58, 60, 62, 64, 66, 68 or 70; preferably 60%-99% identity,
more preferably 70%-97% identity, and most preferably 80%-95%
identity, wherein the G protein immunogen variants retain at least
one epitope that elicits a protective immune response against RSV
without eliciting an immunopathological response or with a reduced
immunopathological response (e.g., eosinophilia). As used herein,
"percent identity" or "% identity" is the percentage value returned
by comparing the whole of the subject polypeptide, peptide, or
variant thereof sequence to a test sequence using a computer
implemented algorithm, typically with default parameters.
[0028] In one preferred embodiment, a G protein immunogen is a
variant of wild-type G protein having a point mutation, wherein an
amino acid at, for example, position 191 (Asn) is changed to an Ala
(see SEQ ID NO:2 and FIG. 3, also referred to as G protein N191A),
and in a more preferred embodiment, a G protein immunogen variant
is a fragment of full length G protein. For example such a G
protein fragment may include from about amino acid 128 to about
amino acid 229, wherein the fragment contains the N191A mutation
(SEQ ID NO:6). In other embodiments, G protein immunogen variants
span amino acids 128 to 229, wherein the variants include double
point mutants, such as P190A and N191A (SEQ ID NO:56), or R188A and
N191A (SEQ ID NO:58). Other point mutants of use in the instant
invention could include those at the Asn at positions 178 (SEQ ID
NO:60) and 179 (SEQ ID NO:62), and at the Lys at positions 196 (SEQ
ID NO:64), 197 (SEQ ID NO:66), 204 (SEQ ID NO:68), or 205 (SEQ ID
NO:70).
[0029] The representative G protein immunogen variants described
herein include an Ala substitution, but the invention is not so
limited and a person of skill in the art would know that other
amino acids could be used for substitutions. Moreover, the variant
immunogens of the instant invention could be made to include one or
more of a variety of mutations, such as point mutations, frameshift
mutations, missense mutations, additions, deletions, and the like,
or the variants can be a result of modifications, such as by
certain chemical substituents, including glycosylation, alkylation,
etc. Each of the variants of the instant disclosure preferably is
capable of eliciting a protective immune response against RSV
without eliciting an immunopathological response or with a reduced
immunopathological response (e.g., eosinophilia).
[0030] As described herein, preferred fragments of G protein,
whether derived from RSV group A or group B, are immunogens that
retain at least one epitope that elicits a protective immune
response against RSV and elicits a reduced immunopathological
response, or is incapable of eliciting an immunopathological
response. In certain embodiments, the immunogen fragments or
variants thereof (e.g., the N191A mutation) have mutations or
variations from wild-type G protein in amino acid sequences that
span from about amino acid 120 to about amino acid 300 of SEQ ID
NO:2, preferably from about amino acid 125 to about amino acid 250,
more preferably from about amino acid 150 to about amino acid 225,
and most preferably from about amino acid 165 to about amino acid
195. In one embodiment, the G protein immunogen fragment includes
amino acids 128 to 229 and mutations can be found in the range of
about amino acids 178 to about 205 of G protein.
[0031] Sequence comparisons can be performed using any standard
software program, such as BLAST, tBLAST, pBLAST, or MegAlign. Still
others include those provided in the Lasergene bioinformatics
computing suite, which is produced by DNASTAR.RTM. (Madison, Wis.).
References for algorithms such as ALIGN or BLAST may be found in,
for example, Altschul, J. Mol. Biol. 219:555-565, 1991; or Henikoff
and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915-10919, 1992.
BLAST is available at the NCBI website
(www.ncbi.nlm.nih.gov/BLAST). Other methods for comparing multiple
nucleotide or amino acid sequences by determining optimal alignment
are well known to those of skill in the art (see, e.g., Peruski and
Peruski, The Internet and the New Biology: Tools for Genomic and
Molecular Research (ASM Press, Inc. 1997); Wu et al. (eds.),
"Information Superhighway and Computer Databases of Nucleic Acids
and Proteins," in Methods in Gene Biotechnology, pages 123-151 (CRC
Press, Inc. 1997); and Bishop (ed.), Guide to Human Genome
Computing, 2nd Edition, Academic Press, Inc., 1998).
[0032] As used herein, "similarity" between two peptides or
polypeptides is generally determined by comparing the amino acid
sequence of one peptide or polypeptide to the amino acid sequence
and conserved amino acid substitutes thereto of a second peptide or
polypeptide. Fragments or portions of the G protein immunogens or
variants thereof of the present description may be employed for
producing the corresponding full-length G protein immunogens by
peptide synthesis; therefore, the fragments may be employed as
intermediates for producing the full-length G protein immunogens.
Similarly, fragments or portions of the nucleic acids of the
present invention may be used to synthesize full-length nucleic
acids of the present disclosure.
[0033] As described herein, G protein immunogens and fragments or
variants thereof of the instant disclosure have an epitope that
elicits a protective immune response without eliciting an
immunopathological response or with a reduced immunopathological
response. The fragments and variants may be identified using in
vivo and in vitro assays known in the art, such as animal
immunization studies (e.g., using a mouse or rabbit model) and
Western immunoblot analysis, respectively, and combinations
thereof. Other examples include plaque reduction assays to assess
whether G protein immunogens and fragments or variants thereof of
the instant description are capable of eliciting an immune
response, particularly a protective (neutralizing) immune response.
Briefly, an animal is immunized with one or more G protein
immunogens, or composition thereof, by subcutaneous administration,
sera is collected from the immunized animals, and then the sera is
tested for its ability to inhibit RSV infection of a cell culture
monolayer (infection being measured as the number of plaques that
form; i.e., "holes" in the monolayer arising from RSV causing cells
to lyse) (see, e.g., Example 8). In addition, altered (reduced or
enhanced) immunopathological responses can be indirectly identified
by, for instance, examining cytokine expression patterns in animals
challenged with RSV after immunization with G protein immunogens of
the invention. For example, specific cytokine levels can be
measured in tissues of interest using a ribonuclease protection
assay (RPA) to deduce whether a type 1 or type 2 response is
prevalent after immunization with a G protein immunogen of the
invention and subsequent challenge with RSV (see Example 9). These
and other assays known in the art can be used to identify G protein
immunogens and fragments or variants thereof that have an epitope
that elicits a protective immune response without eliciting an
immunopathological response or with a reduced immunopathological
response, according to the instant description.
[0034] The RSV G protein polypeptides, fragments thereof, and
fusion proteins thereof, as well as corresponding nucleic acids of
the present invention, are preferably provided in an isolated form,
and in certain preferred embodiments, are purified to homogeneity.
As used herein, the term "isolated" means that the material is
removed from its original or natural environment. For example, a
naturally occurring nucleic acid molecule or polypeptide present in
a living animal or cell is not isolated, but the same nucleic acid
molecule or polypeptide is isolated when separated from some or all
of the co-existing materials in the natural system. The nucleic
acid molecules, for example, could be part of a vector and/or such
nucleic acids or polypeptides could be part of a composition and
still be isolated in that such vector or composition is not part of
its natural environment.
[0035] The present invention also pertains to RSV G protein
immunogens and fragments or variants thereof produced synthetically
or recombinantly, and preferably recombinantly. The immunogenic
polypeptide components of the immunogens may be synthesized by
standard chemical methods, including synthesis by automated
procedure. In general, immunogenic peptides are synthesized based
on the standard solid-phase Fmoc protection strategy with HATU as
the coupling agent. The immunogenic peptide is cleaved from the
solid-phase resin with trifluoroacetic acid containing appropriate
scavengers, which also deprotects side chain functional groups.
Crude immunogenic peptide is further purified using preparative
reverse phase chromatography. Other purification methods, such as
partition chromatography, gel filtration, gel electrophoresis, or
ion-exchange chromatography may be used. Other synthesis techniques
known in the art may be employed to produce similar immunogenic
peptides, such as the tBoc protection strategy, use of different
coupling reagents, and the like. In addition, any naturally
occurring amino acid or derivative thereof may be used, including
D- or L-amino acids and combinations thereof. In particularly
preferred embodiments, a synthetic G protein immunogen of the
invention will have an amino acid sequence that is at least 80%
identical to SEQ ID NOS:2, 6, 8, 10, 12, 14, 16, 18, 20, 22, 56,
58, 60, 62, 64, 66, 68 or 70.
[0036] As described herein, the G protein immunogens and fragments
or variants thereof of certain embodiments may be recombinant,
wherein a desired G protein immunogen is expressed from a
polynucleotide that is operably linked to an expression control
sequence (e.g., promoter) in a nucleic acid expression construct.
In particularly preferred embodiments, a recombinant G protein
immunogen will comprise an amino acid sequence that is at least 80%
identical to SEQ ID NO:2. Some preferable recombinant G protein
immunogens comprise an amino acid sequence of SEQ ID NO:2 or
consist solely of an amino acid sequence as set forth in SEQ ID
NO:2. More preferably, a recombinant G protein immunogens and
variants thereof comprise an amino acid sequence as set forth in
SEQ ID NOS:6, 8, 10, 12, 14, 16, 18, 20, 22, 56, 58, 60, 62, 64,
66, 68 or 70, and more preferably comprise an amino acid sequence
as set forth in SEQ ID NO:6, SEQ ID NO:56 or SEQ ID NO:58. In
preferred embodiments, recombinant G protein immunogens and
fragments or variants thereof have an epitope that elicits a
protective immune response without eliciting an, or with a reduced,
immunopathological response.
[0037] "Nucleic acid" or "nucleic acid molecule" refers to any of
deoxyribonucleic acid (DNA), ribonucleic acid (RNA),
oligonucleotides, fragments generated by the polymerase chain
reaction (PCR), and fragments generated by any of ligation,
scission, endonuclease action, and exonuclease action. Nucleic
acids may be composed of monomers that are naturally occurring
nucleotides (such as deoxyribonucleotides and ribonucleotides),
analogs of naturally occurring nucleotides (e.g.,
.alpha.-enantiomeric forms of naturally-occurring nucleotides), or
a combination of both. Modified nucleotides can have modifications
in sugar moieties and/or in pyrimidine or purine base moieties.
Sugar modifications include, for example, replacement of one or
more hydroxyl groups with halogens, alkyl groups, amines, and azido
groups, or sugars can be functionalized as ethers or esters.
Moreover, the entire sugar moiety may be replaced with sterically
and electronically similar structures, such as aza-sugars and
carbocyclic sugar analogs. Examples of modifications in a base
moiety include alkylated purines and pyrimidines, acylated purines
or pyrimidines, or other well-known heterocyclic substitutes.
Nucleic acid monomers can be linked by phosphodiester bonds or
analogs of such linkages. Analogs of phosphodiester linkages
include phosphorothioate, phosphorodithioate, phosphoroselenoate,
phosphorodiselenoate, phosphoroanilothioate, phosphoranilidate,
phosphoramidate, and the like. The term "nucleic acid" also
includes so-called "peptide nucleic acids," which comprise
naturally occurring or modified nucleic acid bases attached to a
polyamide backbone. Nucleic acids can be either single stranded or
double stranded.
[0038] Further, an "isolated nucleic acid molecule" refers to a
polynucleotide molecule in the form of a separate fragment, or as a
component of a larger nucleic acid construct, which has been
separated from its source cell (including the chromosome it
normally resides in) at least once in a substantially pure form.
For example, a DNA molecule that encodes an RSV polypeptide,
peptide, or variant thereof, which has been separated from an RSV
particle or from a host cell infected with or harboring RSV, is an
isolated DNA molecule. Another example of an isolated nucleic acid
molecule is a chemically synthesized nucleic acid molecule. Nucleic
acid molecules may be comprised of a wide variety of nucleotides,
including DNA, cDNA, RNA, nucleotide analogues or some combination
thereof. In one embodiment, an isolated nucleic acid molecule
comprises a sequence encoding a G protein immunogen or fragment
thereof comprising an amino acid sequence that is at least 80%
identical to SEQ ID NO:2, wherein said G protein immunogen has an
epitope that elicits a protective immune response without eliciting
an, or with a reduced, immunopathological response. In another
embodiment, an isolated nucleic acid molecule comprises a sequence
encoding a G protein immunogen that has an amino acid sequence
comprising or consisting of SEQ ID NO:2. In other embodiments, an
isolated nucleic acid molecule comprises a sequence encoding a G
protein immunogen fragment that comprises an amino acid sequence as
set forth in NOS:6, 8, 10, 12, 14, 16, 18, 20, 22, 56, 58, 60, 62,
64, 66, 68 or 70, and more preferably comprises an amino acid
sequence as set forth in SEQ ID NO:6, SEQ ID NO:56, or SEQ ID
NO:58.
[0039] In certain aspects, the invention relates to nucleic acid
vectors and constructs that include nucleic acid sequences of the
present invention, and in particular to "nucleic acid expression
constructs" that include any polynucleotide encoding an RSV
polypeptide and fragments or variants thereof as provided above. In
another aspect, the instant disclosure pertains to host cells that
are genetically engineered with vectors or constructs of the
invention, and to the production and use in methods for treating or
preventing an RSV infection or eliciting an immune response. The
RSV polypeptides and fragments or variants thereof may be expressed
in mammalian cells, yeast, bacteria or other cells under the
control of appropriate expression control sequences. Cell-free
translation systems may also be employed to produce such proteins
using RNAs derived from the nucleic acid expression constructs of
the present invention. Appropriate cloning and expression vectors
for use with prokaryotic and eukaryotic hosts are described, for
example, by Sambrook et al., Molecular Cloning. A Laboratory
Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), and may
include plasmids, cosmids, shuttle vectors, viral vectors and
vectors comprising a chromosomal origin of replication as disclosed
therein.
[0040] In one embodiment, a nucleic acid expression construct
comprises an expression control sequence operably linked to a
polynucleotide encoding a G protein immunogen or fragment thereof
comprising an amino acid sequence that is at least 80% identical to
SEQ ID NO:2, wherein said G protein immunogen has an epitope that
elicits a protective immune response without eliciting an
immunopathological response or with a reduced immunopathological
response. In certain embodiments, a nucleic acid expression
construct comprises an expression control sequence operably linked
to a polynucleotide encoding a G protein immunogen that has an
amino acid sequence comprising or consisting of SEQ ID NO:2. In
other embodiments, a nucleic acid expression construct comprises an
expression control sequence operably linked to a polynucleotide
encoding a G protein immunogen or fragment thereof comprising an
amino acid sequence as set forth in NOS:6, 8, 10, 12, 14, 16, 18,
20, 22, 56, 58, 60, 62, 64, 66, 68 or 70, and more preferably
comprises an amino acid sequence as set forth in SEQ ID NO:6, SEQ
ID NO:56, or SEQ ID NO:58.
[0041] In other embodiments, the nucleic acid expression constructs
described herein have an inducible promoter, which may be lac, tac,
trc, ara, trp, .lamda. phage, T7 phage, and T5 phage promoter, and
more preferably is a T5 phage promoter/lac operator expression
control sequence (plasmid pT5) as described in U.S. Patent
Application Publication No. 2003/0143685. The "expression control
sequence" refers to any sequence sufficient to allow expression of
a protein of interest in a host cell, including one or more
promoter sequences, enhancer sequences, operator sequences (e.g.,
lacO), and the like. In certain embodiments, the RSV
polypeptide-encoding nucleic acid is in a plasmid, preferably in
plasmid pT5, and the host cell is a bacterium, preferably
Escherichia coli.
[0042] Injection of mammals with gene delivery vehicles (e.g.,
naked DNA) encoding antigens of various pathogens has been shown to
result in protective immune responses (Ulmer et al., Science
259:1745-9, 1993; Boume et al., J Infect. Dis. 173:800-7, 1996;
Hoffman et al., Vaccine 12:1529-33, 1994). Since the original
description of in vivo expression of foreign proteins from naked
DNA injected into muscle tissue (Wolff et al., Science 247:1465-8,
1990), there have been several advances in the design and delivery
of DNA for purposes of vaccination.
[0043] The RSV vaccines described herein are ideally suited for
delivery via naked DNA because antibodies ultimately establish
protective immunity. For example, within one embodiment,
polynucleotide sequences that encode a G protein immunogen or
fragment thereof are ligated into plasmids that are specifically
engineered for mammalian cell expression (see, e.g., Hartikka et
al., Hum Gene Ther 7:1205-17, 1996, which contains the
promoter/enhancer element from cytomegalovirus early gene, the
signal peptide from human tissue plasminogen activator and a
terminator element from the bovine growth hormone gene). The RSV
polypeptides can be cloned into a plasmid that is used to transfect
human cell lines to assure recombinant protein expression. The
plasmid may be propagated in bacteria, such as E. coli, and
purified in quantities sufficient for immunization studies by
cesium chloride gradient centrifugation. Animals, such as mice, can
be immunized with, for example, 50 .mu.g of an isolated recombinant
plasmid in 50 .mu.l saline intramuscularly (i.m.). Booster
injections of the same dose may be further given at three and six
week intervals after the initial injection.
[0044] A wide variety of other gene delivery vehicles can likewise
be utilized within the context of the present invention, including
viruses, retrotransposons and cosmids. Representative examples
include adenoviral vectors (e.g., WO 94/26914, WO 93/9191; Yei et
al., Gene Therapy 1:192-200, 1994; Kolls et al., PNAS
91(1):215-219, 1994; Kass-Eisler et al., PNAS 90(24):11498-502,
1993; Guzman et al., Circulation 88(6):2838-48, 1993; Guzman et
al., Cir. Res. 73(6):1202-1207, 1993; Zabner et al., Cell
(2):207-216, 1993; Li et al., Hum Gene Ther. 4(4):403-409, 1993;
Caillaud et al., Eur. J. Neurosci. 5(10):1287-1291, 1993),
adeno-associated type 1 ("AAV-1") or adeno-associated type 2
("AAV-2") vectors (see WO 95/13365; Flotte et al., PNAS
90(22):10613-10617, 1993), hepatitis delta vectors, live,
attenuated delta viruses, vaccinia vectors and herpes viral vectors
(e.g., U.S. Pat. No. 5,288,641), as well as vectors which are
disclosed within U.S. Pat. No. 5,166,320. Other representative
vectors include retroviral vectors (e.g., EP 0 415 731; WO
90/07936; WO 91/02805; WO 94/03622; WO 93/25698; WO 93/25234; U.S.
Pat. No. 5,219,740; WO 93/11230; WO 93/10218). Methods of using
such vectors in gene therapy are well known in the art (see, e.g.,
Larrick, J. W. and Burck, K. L., Gene Therapy: Application of
Molecular Biology, Elsevier Science Publishing Co., Inc., New York,
N.Y., 1991; and Kreigler, M., Gene Transfer and Expression: A
Laboratory Manual, W.H. Freeman and Company, New York, 1990).
[0045] Gene-delivery vehicles may be introduced into a host cell
utilizing a vehicle, or by various physical methods. Representative
examples of such methods include transformation using calcium
phosphate precipitation (Dubensky et al., PNAS 81:7529-7533, 1984),
direct microinjection of such nucleic acid molecules into intact
target cells (Acsadi et al., Nature 352:815-818, 1991), and
electroporation whereby cells suspended in a conducting solution
are subjected to an intense electric field in order to transiently
polarize the membrane, allowing entry of the nucleic acid
molecules. Other procedures include the use of nucleic acid
molecules linked to an inactive adenovirus (Cotton et al., PNAS
89:6094, 1990), lipofection (Felgner et al., Proc. Natl. Acad. Sci.
USA 84:7413-7417, 1989), microprojectile bombardment (Williams et
al., PNAS 88:2726-2730, 1991), polycation compounds (such as
polylysine), receptor specific ligands, liposomes entrapping the
nucleic acid molecules, spheroplast fusion whereby E. coli
containing the nucleic acid molecules are stripped of their outer
cell walls and fused to animal cells using polyethylene glycol,
viral transduction, (Cline et al., Pharmac. Ther. 29:69, 1985; and
Friedmann et al., Science 244:1275, 1989), and DNA ligand (Wu et
al, J. of Biol. Chem. 264:16985-16987, 1989), as well as psoralen
inactivated viruses such as Sendai or Adenovirus.
[0046] Serum from a subject immunized with gene delivery vehicles
containing RSV polypeptide immunogens and fragments or variants
thereof, and fusions thereof can be assayed for total antibody
titer by ELISA using native RSV polypeptides as the antigen. Serum
protective antibodies may be assayed as described herein or as
known in the art. Protective efficacy of DNA RSV polypeptide
vaccines can be determined by, for example, direct animal
protection assays (i.e., challenge infection studies) using an RSV
serotype that is represented in the pharmaceutical composition or
vaccine (i.e., challenge infection studies).
[0047] As will be appreciated by those of ordinary skill in the
art, an RSV polypeptide-encoding nucleic acid may be a variant of
the natural sequence due to, for example, the degeneracy of the
genetic code (including homologs or strain variants or other
variants). Briefly, such "variants" may result from natural
polymorphisms or may be synthesized by recombinant methodology
(e.g., to obtain codon optimization for expression in a particular
host) or chemical synthesis, and may differ from wild-type
polypeptides by one or more amino acid substitutions, insertions,
deletions, and the like. Variants encompassing conservative amino
acid substitutions include, for example, substitutions of one
aliphatic amino acid for another, such as Ile, Val, Leu, or Ala or
substitutions of one polar residue for another, such as between Lys
and Arg, Glu and Asp, or Gln and Asn. Such substitutions are well
known in the art to provide variants having similar physical
properties, structural properties, and functional activities, such
as for example, the ability to elicit and cross-react with similar
antibodies (e.g., antibodies that specifically bind to wild-type G
protein). Other variants include nucleic acids sequences that
encode G protein immunogen fragments having at least 50% to 100%
amino acid identity to SEQ ID NOS:2, 6, 8, 10, 12, 14, 16, 18, 20,
22, 56, 58, 60, 62, 64, 66, 68 or 70. Preferred embodiments are
those variants having greater than 90% or 95% identity with the
amino acid sequence of SEQ ID NOS:2, 6, 8, 10, 12, 14, 16, 18, 20,
22, 56, 58, 60, 62, 64, 66, 68 or 70.
[0048] In certain embodiments, the present invention includes any
of the aforementioned degenerate nucleic acid molecules that encode
G protein immunogens and fragments or variants thereof comprising
an amino acid sequence as set forth in SEQ ID NOS:2, 6, 8, 10, 12,
14, 16, 18, 20, 22, 56, 58, 60, 62, 64, 66, 68 or 70, and that
retain functional activity (such as having an epitope that elicits
a protective immune response without eliciting an
immunopathological response or with a reduced immunopathological
response). In another aspect, contemplated are nucleic acid
molecules that encode G protein immunogens and fragments or
variants thereof having conservative amino acid substitutions or
deletions or substitutions, such that the RSV polypeptide
variant(s) retain (from wild-type) or have at least one epitope
capable of eliciting antibodies specific for one or more RSV
strains.
[0049] In certain aspects, a nucleic acid sequence may be modified
to encode an RSV immunogen or functional variant thereof wherein
specific codons of the nucleic acid sequence have been changed to
codons that are favored by a particular host and can result in
enhanced levels of expression (see, e.g., Haas et al., Curr. Biol.
6:315, 1996; Yang et al., Nucleic Acids Res. 24:4592, 1996). For
example, certain codons of the immunogenic peptides can be
optimized, without changing the primary sequence of the peptides,
for improved expression in Escherichia coli. By way of illustration
and not limitation, arginine (Arg) codons of AGG/AGA can be changed
to the Arg codons of CGT/CGC. Similarly, AGG/AGA Arg codons can be
optimized to CGT/CGC codons. As is known in the art, codons may be
optimized for a host in which the G protein immunogens and
fragments or variants thereof are to be expressed, including
bacteria, fungi, insect cells, plant cells, and mammalian cells.
Additionally, codons encoding different amino acids may be changed
as well, wherein one or more codons encoding different amino acids
may be altered simultaneously as would best suit a particular host
(e.g., codons for arginine, glycine, leucine, and serine may all be
optimized or any combination thereof). Exemplary nucleic acid
sequences with codons optimized for expression in bacteria include
sequences as set forth in SEQ ID NOS:23, 25, 27, 29, 31 and 33.
These nucleic acid sequences encode G protein immunogen fragment
fusion proteins (i.e., fused to thioredoxin or a hexahistidine tag)
as set forth in SEQ ID NOS:24, 26, 28, 30, 32 and 34, respectively.
Alternatively, codon optimization may result in one or more changes
in the primary amino acid sequence, such as a conservative amino
acid substitution, addition, deletion, and combinations
thereof.
[0050] While particular embodiments of isolated nucleic acids
encoding RSV immunogens are depicted in SEQ ID NOS:1, 3, 5, 7, 9,
11, 13, 15, 17, 19, 21, 55, 57, 59, 61, 63, 65 67 or 69, within the
context of the present disclosure, reference to one or more
isolated nucleic acids includes variants of these sequences that
are substantially similar in that they encode native or non-native
RSV polypeptides with similar structure and similar functional
ability to elicit specific antibodies to at least one G protein
epitope contained in the RSV polypeptides of SEQ ID NOS:2, 4, 6, 8,
10, 12, 14, 16, 18, 20, 22, 56, 58, 60, 62, 64, 66, 68 or 70. As
used herein, the nucleotide sequence is deemed to be "substantially
similar" when: (a) the nucleotide sequence is derived from the
coding region of an RSV G protein gene (including, for example,
portions of the sequence or homologous variations of the sequences
discussed herein) and contains a G protein epitope with
substantially the same ability to elicit a protective immune
response without eliciting an, or with a reduced,
immunopathological response; (b) the nucleotide sequence is capable
of hybridization to the nucleotide sequences of the present
invention under moderate or high stringency; (c) the nucleotide
sequences are degenerate (i.e., sequences which code for the same
amino acids using a different codon sequences) as a result of the
genetic code to the nucleotide sequences defined in (a) or (b); or
(d) is a complement of any of the sequences described in (a), (b)
or (c).
[0051] As used herein, two nucleotide sequences are said to
"hybridize" under conditions of a specified stringency when stable
hybrids are formed between substantially complementary nucleic acid
sequences. Stringency of hybridization refers to a description of
the environment under which hybrids are annealed and washed (i.e.,
conditions under which annealed hybrids remain hybridized or
annealed), which typically includes varying ionic strength and
temperature. Other factors that might affect hybridization include
the probe size and the length of time the hybrids are allowed to
form. For example, "high," "medium" and "low" stringency encompass
the following conditions or equivalent conditions thereto: high
stringency is 0.1.times.SSPE or SSC, 0.1% SDS, 65.degree. C.;
medium stringency is 0.2.times.SSPE or SSC, 0.1% SDS, 50.degree.
C.; and low stringency is 1.0.times.SSPE or SSC, 0.1% SDS,
50.degree. C. As used herein, the term "high stringency conditions"
means that one or more sequences will remain hybridized only if
there is at least 95%, and preferably at least 97%, identity
between the sequences. In preferred embodiments, the nucleic acid
sequences that remain hybridized to a G protein immunogen-encoding
nucleic acid molecule encode polypeptides that retain at least one
epitope of a G protein immunogen of any one of SEQ ID NOS:2, 6, 8,
10, 12, 14, 16, 18, 20, 22, 56, 58, 60, 62, 64, 66, 68 or 70, and
have an epitope with substantially the same ability to elicit a
protective immune response without eliciting an immunopathological
response or with a reduced immunopathological response.
[0052] Methods for producing the RSV polypeptides of the subject
invention are also provided wherein any of the nucleic acid
molecules and host cells described herein may be used. In a
preferred embodiment, a method of producing a G protein immunogen
and fragments or variants thereof (having at least one epitope that
elicits a protective immune response without eliciting an, or with
a reduced, immunopathological response) comprises culturing a host
cell containing a nucleic acid expression vector comprising at
least one expression control sequence operably linked to a nucleic
acid molecule encoding an RSV polypeptide, such as an RSV G protein
immunogen and fragment or variant thereof as set forth in any one
of SEQ ID NOS:2, 6, 8, 10, 12, 14, 16, 18, 20, 22, 56, 58, 60, 62,
64, 66, 68 or 70, under conditions and for a time sufficient for
expression of the polypeptide. In one embodiment, an RSV G protein
immunogen and fragment or variant thereof is produced by this
method, and more preferably the RSV polypeptides produced comprise
an amino acid sequence as set forth in SEQ ID NOS: 2, 6, 8, 10, 12,
14, 16, 18, 20, 22, 56, 58, 60, 62, 64, 66, 68 or 70, and more
preferably the RSV polypeptides produced comprise an amino acid
sequence as set forth in SEQ ID NO:6, 56, or 58.
[0053] In certain embodiments, multivalent vaccines are
contemplated. For example, such multivalent compositions may
comprise a combination of two or more different G protein
immunogens, or a combination of one or more G protein immunogens
with one or more other RSV immunogens (such as an F protein or an M
protein immunogen). The combination of antigens may be formulated
as a cocktail (i.e., a mixture of a plurality of different
immunogens), or the combination may be a plurality of different
immunogens conjugated, linked or fused together (chemically or
recombinantly). In addition, the fused immunogens may have one or
more immunogens reiterated at least once within the multivalent
fusion protein, which reiteration may occur at the amino-terminal
end, the carboxy-terminal end, an internal position of a selected
multivalent immunogen polypeptide, at multiple positions, or any
combination thereof. For example, such multivalent hybrid RSV
immunogens may comprise one or more peptide fragments of the G
protein and one or more peptides fragments of an F protein or M
protein of RSV, and any combination thereof. In certain
embodiments, such multivalent hybrid RSV multivalent hybrid RSV
immunogen vaccine compositions may combine immunogenic epitopes
from different RSV antigenic groups, for example, immunogens from
subgroup A viruses (e.g., Long and A2) or subgroup B viruses (e.g.,
CH-18537 and 8/60), or immunogens from both subgroup A and B
viruses (or any other RSV subgroups that are found to, for example,
infect humans).
[0054] In some embodiments, the RSV immunogens may be linked by,
for example, at least two amino acids encoded by a nucleic acid
sequence that is a restriction enzyme recognition site, wherein the
restriction sites may be any one or more of BamHI, ClaI, EcoRI,
HindIII, KpnI, NcoI, NheI, PmlI, PstI, SalI, XhoI, and the like.
Additional amino acid linkers may also be added synthetically, as
is known in the art and described herein. Preferably, the
additional amino acids do not create any identity in sequence
encompassing a five amino acid stretch of a human protein so as to
minimize the possibility of eliciting human tissue cross-reactive
antibodies. In addition, the hybrid polypeptides of the subject
invention may further comprise at least one additional
carboxy-terminal amino acid, wherein the additional amino acid is a
D- or an L-amino acid. Any of the twenty naturally occurring amino
acids or derivatives thereof may be added, such as cysteine,
histidine, leucine, and glutamic acid. For example, the addition of
cysteine may be useful to attach (e.g., enzymatically or by
chemical cross-linking) other constituents, such as a lipid, a
carrier protein, a tag, an enzyme, and the like.
[0055] As described herein, the invention also provides RSV
immunogen fusion proteins comprising a G protein immunogen or
fragment thereof fused to an additional functional or
non-functional polypeptide sequence that permits, for example,
detection, isolation, and purification of the hybrid polypeptide
fusion proteins. For instance, an additional functional polypeptide
sequence may be a tag sequence, which includes fusion proteins that
may in certain embodiments be detected, isolated or purified by
protein-protein affinity (e.g., receptor-ligand), metal affinity or
charge affinity methods. In certain other embodiments the hybrid
polypeptide fusion proteins may be detected by specific protease
cleavage of a fusion protein having a sequence that comprises a
protease recognition sequence, such that the hybrid polypeptides
may be separable from the additional polypeptide sequence. In
addition, the hybrid polypeptides may be made synthetically
including additional amino acids, a carrier protein, a hydrophobic
portion or moiety (e.g., a lipid), or a tag sequence, which may be
located at the amino-terminal end, carboxy-terminal end, or at a
site internal (non-terminal) of the fusion protein. In particularly
preferred embodiments, for example, recombinant RSV immunogens are
fused in-frame to a tag, which tag may be any one of alkaline
phosphatase, thioredoxin (Trx), .beta.-galactosidase, hexahistidine
(6.times.His), FLAG.RTM. epitope tag (DYKDDDDK, SEQ ID NO:71), GST
or the like, and any combination thereof.
[0056] Preferred embodiments include hybrid polypeptide fusion
proteins that facilitate affinity detection and isolation of the
hybrid polypeptides, and may include, for example, poly-His or the
defined antigenic peptide epitopes described in U.S. Pat. No.
5,011,912 and in Hopp et al., (1988 Bio/Technology 6:1204), or the
XPRESS.TM. epitope tag (DLYDDDDK, SEQ ID NO:72; Invitrogen,
Carlsbad, Calif.), or thioredoxin. The affinity sequence may be a
hexa-histidine tag as supplied by a vector. For example, a pBAD/H
is (Invitrogen), a pET vector (Invitrogen) or a pQE vector (Qiagen,
Valencia, Calif.) can provide a polyhistidine tag for purification
of the mature protein fusion from a particular host, such as a
bacterium, using a nickel affinity column. Alternatively, the
affinity sequence may be added either synthetically or engineered
into the primers used to recombinantly generate the nucleic acid
sequence (e.g., using the polymerase chain reaction) encoding an
immunogenic peptide of RSV. Optionally, any of the aforementioned G
protein immunogens and fragments or variants thereof, and fusion
proteins thereof, may also have a hydrophobic portion (anchor or
foot) that is conjugated, linked or fused (chemically or
recombinantly) to the amino-terminal end or carboxy-terminal end.
Representative hydrophobic moieties include an amino acid sequence
of at least five amino acids, such as MFLLAVFYGG (SEQ ID NO:35) or
GGYFVALLF (SEQ ID NO:36), or a lipid.
[0057] In certain embodiments, RSV immunogens are fused to a
thioredoxin or a polyhistidine tag, which are encoded by a
recombinant nucleic acid sequence encoding such a fusion protein.
In preferred embodiments, RSV G protein immunogen fragments are
fused to a thioredoxin and a polyhistidine tag, which are encoded
by a nucleic acid sequence as set forth in SEQ ID NOS: 23 or 25.
Exemplary amino acid sequences of RSV G protein immunogen fragments
fused to a thioredoxin and a polyhistidine tag are set forth in SEQ
ID NOS:24 and 26. In related embodiments, provided are nucleic acid
sequences that encode an RSV G protein immunogen fusion protein
further comprising a nucleic acid sequence that encodes a
hydrophobic moiety or foot linked or fused to the G immunogen
fusion protein, as found in the sequences set forth in SEQ ID
NOS:27, 29, 31 or 33. Exemplary amino acid sequences of RSV G
protein immunogen fragments fused to a thioredoxin and a
polyhistidine tag, and further comprising a hydrophobic portion or
foot are set forth in SEQ ID NOS:28, 30, 32 and 34. In preferred
embodiments, the hydrophobic moiety is an amino acid sequence of
MFLLAVFYGG (SEQ ID NO:35) fused to the amino-terminal end of the
fusion protein or GGYFVALLF (SEQ ID NO:36) fused to the
carboxy-terminal end of the fusion protein.
[0058] A fusion protein may comprise a hydrophobic moiety fused to
the amino-terminal end or carboxy-terminal end of a G protein
immunogen or fragment thereof. Alternatively, fusion protein may
comprise a hydrophobic portion fused to a linker (e.g., one or more
amino acids, preferably two or four) which in turn is fused to the
amino-terminal end or carboxy-terminal end of a G protein immunogen
or fragment thereof. In still other embodiments, a fusion protein
may comprise a hydrophobic moiety fused to one or more amino acid
sequences (e.g., a tag, such as a thioredoxin or a polyhistidine)
which in turn is fused to the amino-terminal end of a G protein
immunogen or fragment thereof, or a fusion protein may comprise one
or more amino acid sequences (e.g., a tag, such as a thioredoxin or
a polyhistidine) fused to the amino-terminal end of a G protein
immunogen or fragment thereof which in turn is fused to a
hydrophobic portion. As will be appreciated by those of skill in
the art, a fusion protein of the instant disclosure may be
constructed to contain one or more G protein immunogens or
fragments and variants thereof, one or more linkers, one or more
additional amino acid tag sequences, one or more hydrophobic
portions, or any combination thereof.
Therapeutic Formulations and Methods of Use
[0059] This description also relates to pharmaceutical compositions
that contain one or more RSV immunogens, which may be used to
elicit an immune response without the concomitant
immunopathological response or at least a reduced
immunopathological response. This description further relates to
methods for treating and preventing RSV infections by administering
to a subject a G protein immunogen or fragment and variants
thereof, fusion protein, multivalent immunogen, or a mixture of
such immunogens at a dose sufficient to elicit antibodies specific
for RSV, as described herein. G protein immunogens or fragments and
variants thereof, or a cocktail of such immunogens are preferably
part of a pharmaceutically acceptable composition when used in the
methods of the present invention.
[0060] By way of background, natural or experimental infection of
an animal or human subject does not appear to elicit a CD8.sup.+
CTL immune response recognizing G protein, while in contrast the F
protein does elicit a CD8.sup.+ CTL immune response. Accordingly, a
G plus F composite RSV antigen vaccine of the instant description
is expected to elicit both a CD4.sup.+ and a CD8.sup.+ protective
immune response, without eliciting an, or with a reduced,
immunopathological proliferative lymphocyte response, such a
response being harmful or otherwise unwanted. Moreover, the use of
proteosome technology-based components combined with RSV antigen(s)
may influence a shift in the immune response raised to an RSV
antigen from a predominantly type 2 response towards a preferential
type 1 response (as determined by cytokine profiles known by those
of ordinary skill in the art), and thereby eliminating or reducing,
in a statistically significant manner, an undesired eosinophilic
response, an undesired IgE response or both, following immunization
with a vaccine or pharmaceutical composition of the instant
description. For example, by combining one or more MHC class I
CD8.sup.+ immunogenic epitopes of the RSV F protein with one or
more CD4.sup.+ MHC class II immunogenic epitopes contained in RSV G
protein.
[0061] As known in the art, the pattern of cytokine expression and
CD4.sup.+ lymphocyte activation at the time of first exposure to an
RSV antigen influences the pattern of immune responses to
subsequent exposures. Therefore, along with protection from
respiratory disease and eosinophilia, immunogenic compositions of
the instant application may prove to be useful in protecting
against childhood asthma associated with an RSV infection. In one
preferred embodiment, for example, a vaccine of the instant
invention is capable of eliciting an immune response that protects
from or otherwise moderates the pathological consequences of an RSV
infection, while at the same time ablating or otherwise diminishing
a subsequent IgE antibody response to common allergens.
[0062] In certain embodiments, the invention provides a composition
comprising a respiratory syncytial virus G protein immunogen
formulated with a proteosome or a liposome, wherein said G protein
immunogen comprises an amino acid sequence that is at least 80%
identical to SEQ ID NO:2 or fragment thereof and wherein said G
protein immunogen or fragment thereof has an epitope that elicits a
protective immune response without eliciting an, or with a reduced,
immunopathological response. One embodiment is a G protein
immunogen comprising an amino acid sequence as set forth in SEQ ID
NO:2 or consisting of SEQ ID NO:2. In other preferred embodiments
are G protein immunogens that comprise an amino acid sequence
selected from SEQ ID NOS:6, 8, 10, 12, 14, 16, 18, 20, 22, 56, 58,
60, 62, 64, 66, 68 or 70, more preferably SEQ ID NO:6, SEQ ID NO:56
or SEQ ID NO:58. Preferably, liposomes formulated to contain one or
more RSV immunogens further comprise Deinococcus radiodurans lipids
or .alpha.-galactosylphosphotidylglycerolalkylamine. The addition
of such lipids in a liposome can enhance the efficacy of an RSV
vaccine composition by increasing protective immunity and
suppressing harmful eosinophilia (see, e.g., Huang and Anderson,
Vaccine 20:1586, 2002).
[0063] Respiratory syncytial virus immunogens of the present
invention may further include a covalently attached hydrophobic
moiety. A hydrophobic moiety may be, for example, an amino acid
sequence or a lipid, as disclosed in U.S. Pat. No. 5,726,292. In
certain embodiments, the hydrophobic moiety is an amino acid
sequence of MFLLAVFYGG (SEQ ID NO:35) fused to the amino-terminal
end of an immunogen or GGYFVALLF (SEQ ID NO:36) fused to the
carboxy-terminal end of an immunogen. Naturally occurring RSV G
protein contains a hydrophobic transmembrane amino acid sequence,
which may function as a hydrophobic moiety according to the instant
invention. In one embodiment, an RSV composition (e.g., a vaccine
composition) of the instant application comprises an RSV G protein
immunogen or fragment thereof as described herein formulated with a
proteosome or protollin. When formulated with a proteosome or
protollin, the G protein immunogens preferably further comprise a
hydrophobic moiety, which may be composed of a hydrophobic amino
acid sequence or a lipid (as used herein, lipid refers to a
solubility characteristic and, therefore, includes alkyls,
arylalkls, aryls, fatty acids, glycerides and glyceryl ethers,
phospholipids, sphingolipids, long chain alcohols, steroids,
vitamins, and the like). In certain embodiments, the G protein
immunogens, with or without a hydrophobic moiety, may further
contain a second amino acid sequence to form a fusion, wherein the
second amino acid sequence is a tag, carrier, enzyme or a
combination thereof, as described herein. One preferred RSV vaccine
of the instant invention can comprise a non-infectious RSV
polypeptide or fragment thereof that is highly immunogenic and
capable of immunoneutralizing virus growth. In preferred
embodiments of the instant invention, such an RSV subunit vaccine
has reduced or no unwanted immunopathological side effects (e.g.,
eosinophilia or asthma) in a vaccinated subject, such as a human or
animal.
[0064] The pharmaceutical composition will preferably include at
least one of a pharmaceutically acceptable vehicle, carrier,
diluent, or excipient, in addition to one or more RSV immunogen or
fusion protein thereof and, optionally, other components. For
example, pharmaceutically acceptable carriers suitable for use with
a composition of a G protein immunogen or fusion protein thereof,
or cocktail of two or more G protein immunogens or fusion proteins
thereof, or cocktail of G, F, and M immunogens or fusion proteins
thereof, may include, for example, a thickening agent, a buffering
agent, a solvent, a humectant, a preservative, a chelating agent,
an adjuvant, and the like, and combinations thereof.
[0065] Exemplary adjuvants include alum (aluminum hydroxide,
REHYDRAGEL.RTM.), aluminum phosphate, proteosome adjuvant with LPS
(protollin) or without LPS (see, e.g., U.S. Pat. Nos. 5,726,292 and
5,985,284, and U.S. Patent Application Publication Nos.
2001/0053368 and US 2003/0044425), virosomes, liposomes with and
without Lipid A, Detox (Ribi/Corixa), MF59, or other oil and water
emulsions type adjuvants, such as nanoemulsions (see, e.g., U.S.
Pat. No. 5,716,637) and submicron emulsions (see, e.g., U.S. Pat.
No. 5,961,970), and Freund's complete and incomplete.
Pharmaceutically acceptable carriers for therapeutic use are well
known in the pharmaceutical art, and as described herein and, for
example, in Remington's Pharmaceutical Sciences, Mack Publishing
Co. (A. R. Gennaro, ed., 18.sup.th Edition, 1990) and in CRC
Handbook of Food, Drug, and Cosmetic Excipients, CRC Press LLC (S.
C. Smolinski, ed., 1992).
[0066] In certain embodiments, the G protein immunogens and
fragments or variants thereof (including fusion proteins and
multivalent compositions) are formulated with proteosome. As used
herein, "proteosome" or "projuvant" refers to preparations of outer
membrane proteins (OMPs, also known as porins) from Gram-negative
bacteria, such as Neisseria species (see, e.g., Lowell et al., J.
Exp. Med. 167:658, 1988; Lowell et al., Science 240:800, 1988;
Lynch et al., Biophys. J. 45:104, 1984; Lowell, in "New Generation
Vaccines" 2nd ed., Marcel Dekker, Inc., New York, Basil, Hong Kong,
page 193, 1997; U.S. Pat. No. 5,726,292; U.S. Pat. No. 4,707,543),
which are useful as a carrier or an adjuvant for immunogens, such
as bacterial or viral antigens. Proteosomes are hydrophobic and
safe for human use, and comparable in size to certain viruses.
Proteosomes have the interesting ability to auto-assemble into
vesicle or vesicle-like OMP clusters of 20-800 nm, and to
noncovalently incorporate, coordinate, associate (e.g.,
electrostatically or hydrophobically), or otherwise cooperate with
protein antigens (Ags), particularly antigens that have a
hydrophobic moiety. Any preparation method that results in the
outer membrane protein component in vesicular or vesicle-like form,
including multi-molecular membranous structures or molten
globular-like OMP compositions of one or more OMPs, is included
within the definition of Proteosome. Proteosomes may be prepared,
for example, as described in the art (see, e.g., U.S. Pat. No.
5,726,292 or 5,985,284).
[0067] In certain embodiments, the G protein immunogens and
fragments or variants thereof (including fusion proteins and
multivalent compositions) are formulated with protollin. As used
herein, "proteosome:LPS" or "protollin" (also known as "IVX-908")
refers to preparations of projuvant admixed as described herein
with at least one kind of liposaccharide to provide an OMP-LPS
composition (which can function as an immunostimulatory
composition). Thus, the OMP-LPS adjuvant can be comprised of two of
the basic components of Protollin, which include (1) an outer
membrane protein preparation of Proteosomes (i.e., projuvant)
prepared from Gram-negative bacteria, such as Neisseria
meningitides, and (2) a preparation of one or more liposaccharides.
It is also contemplated that components of Protollin may be or
include lipids, glycolipids, glycoproteins, small molecules, or the
like. The Protollin may be prepared, for example, as described in
U.S. Patent Application Publication No. 2003/0044425.
[0068] Projuvant is generally used in conjunction with antigens
(naturally-occurring or modified) that possess a naturally
occurring, modified, or supplementary hydrophobic moiety or portion
(also referred to as a "foot" or "anchor"). Protollin (containing
exogenously added LPS) can also be used with an antigen that does
not contain a hydrophobic foot domain and that can be largely
hydrophilic in nature. Protollin can be admixed or combined with an
antigen containing a hydrophobic foot, an antigen lacking a
hydrophobic foot, or with a combination of antigens having and not
having a hydrophobic portion or foot.
[0069] As used herein, "liposaccharide" (such as that used in
preparing protollin) refers to native (isolated or prepared
synthetically with a native structure) or modified
lipopolysaccharide or lipooligosaccharide (collectively, also
referred to as "LPS") derived from Gram-negative bacteria, such as
Shigella flexneri or Plesiomonas shigelloides, or other
Gram-negative bacteria (including Alcaligenes, Bacteroides,
Bordetella, Borrellia, Brucella, Campylobacter, Chlamydia,
Citrobacter, Edwardsiella, Ehrlicha, Enterobacter, Escherichia,
Francisella, Fusobacterium, Gardnerella, Hemophillus, Helicobacter,
Klebsiella, Legionella, Leptospira (including Leptospira
interrogans), Moraxella, Morganella, Neiserria, Paste urella,
Proteus, Providencia, other Plesiomonas, Porphyromonas (including
Porphyromonas gingivalis), Prevotella, Pseudomonas, Rickettsia,
Salmonella, Serratia, other Shigella, Spirillum, Veillonella,
Vibrio, or Yersinia species). The liposaccharide may be in a
detoxified form (i.e., having the Lipid A core removed) or may be
in a form that has not been detoxified. In the instant disclosure,
the liposaccharide need not be and preferably is not
detoxified.
[0070] The two components of an OMP-LPS adjuvant may be formulated
at specific initial ratios to optimize interaction between the
components resulting in stable association and formulation of the
components for use in the preparation of an immunogenic composition
of the invention. The process generally involves the mixing of
components in a selected detergent solution (e.g., Empigen.RTM. BB,
Triton.RTM. X-100, or Mega-10) and then effecting complexing of the
OMP and LPS components while reducing the amount of detergent to a
predetermined, preferred concentration, by dialysis or, preferably,
by diafiltration/ultrafiltration methodologies. Mixing,
co-precipitation, or lyophilization of the two components may also
be used to effect an adequate and stable association or
formulation. In a preferred embodiment, an immunogenic composition
comprises one or more G protein immunogens and an adjuvant, wherein
the adjuvant comprises a Projuvant (i.e., Proteosome) and
liposaccharide.
[0071] In certain embodiments, the final liposaccharide content by
weight as a percentage of the total Proteosome protein can be in a
range from about 1% to about 500%, more preferably in range from
about 10% to about 200%, or in a range from about 30% to about
150%. Another embodiment includes an adjuvant wherein the
Proteosomes are prepared from Neisseria meningitides and the
liposaccharide is prepared from Shigella flexneri or Plesiomonas
shigelloides, and the final liposaccharide content is between 50%
to 150% of the total Proteosome protein by weight. In another
embodiment, Proteosomes are prepared with endogenous
lipooligosaccharide (LOS) content ranging from about 0.5% up to
about 5% of total OMP. Another embodiment of the instant invention
provides Proteosomes with endogenous liposaccharide in a range from
about 12% to about 25%, and in a preferred embodiment between about
15% and about 20% of total OMP. The instant disclosure also
provides a composition containing liposaccharide derived from any
Gram-negative bacterial species, which may be from the same
Gram-negative bacterial species that is the source of Proteosomes
or is a different bacterial species.
[0072] In certain embodiments, the Proteosome or Protollin to G
protein immunogen ratio in the immunogenic composition is greater
than 1:1, greater than 2:1, greater than 3:1 or greater than 4:1.
The ratio can be as high as 8:1 or higher. In other embodiments,
the ratio of Proteosome or Protollin to coronavirus antigen of the
immunogenic composition ranges from about 1:1 to about 1:500,
preferably the ratio is at least 1:5, at least 1:10, at least 1:20,
at least 1:50, or at least 1:100. An advantage of Protollin:G
protein immunogen ratios ranging from 1:2 to 1:200 is that the
amount of Proteosome-based adjuvant can be reduced dramatically
with no significant effect on the ability of a G protein immunogen
to elicit an immune response.
[0073] As used herein, "pharmaceutically acceptable salt" refers to
salts of the compounds of the present invention derived from the
combination of such compounds and an organic or inorganic acid
(acid addition salts) or an organic or inorganic base (base
addition salts). The compounds of the present invention may be used
in either the free base or salt forms, with both forms being
considered as being within the scope of the present invention.
[0074] In addition, the pharmaceutical composition of the instant
invention may further include a diluent or excipient, such as water
or phosphate buffered saline (PBS). Preferably, a diluent or
excipient is PBS with a final phosphate concentration range from
about 0.1 mM to about 1 M, more preferably from about 0.5 mM to
about 500 mM, even more preferably from about 1 mM to about 50 mM,
and most preferably from about 2.5 mM to about 10 mM; and the final
salt concentration ranges from about 100 mM to about 200 mM and
most preferably from about 125 mM to about 175 mM. Preferably, the
final PBS concentration is about 5 mM phosphate and about 150 mM
salt (such as NaCl). In certain embodiments, pharmaceutical
compositions of the instant disclosure comprising any of the herein
described RSV immunogens or cocktails of RSV immunogens are
sterile.
[0075] The compositions can be sterile either by preparing them
under an aseptic environment or they can be terminally sterilized
using methods available in the art. Many pharmaceuticals are
manufactured to be sterile and this criterion is defined by the USP
XXII <1211>. Sterilization in this embodiment may be
accomplished by a number of means accepted in the industry and
listed in the USP XXII <1211>, including gas sterilization,
ionizing radiation or filtration. Sterilization may be maintained
by what is termed aseptic processing, defined also in USP XXII
<1211>. Acceptable gases used for gas sterilization include
ethylene oxide. Acceptable radiation types used for ionizing
radiation methods include gamma, for instance from a cobalt 60
source and electron beam. A typical dose of gamma radiation is 2.5
MRad. When appropriate, filtration may be accomplished using a
filter with suitable pore size, for example 0.22 .mu.m and of a
suitable material, for instance Teflon.RTM.. The term "USP" refers
to U.S. Pharmacopeia (see www.usp.org; Rockville, Md.).
[0076] The present description also pertains to methods for
treating or preventing RSV infection, comprising administering to a
subject in need thereof a composition comprising at least one
respiratory syncytial virus G protein immunogen or fragment thereof
comprising an amino acid sequence that is at least 80% identical to
SEQ ID NO: 2, wherein the G protein immunogen has an epitope that
elicits a protective immune response without eliciting an
immunopathological response or with a reduced immunopathological
response, and pharmaceutically acceptable carrier, diluent, or
excipient, at a dose sufficient to elicit an immune response
specific for one or more G protein immunogen or fragment thereof.
In certain embodiments, an infection is due to a subgroup A,
subgroup B, or both subgroups A and B of RSV. In certain preferred
embodiments, the G protein immunogens used in any of the
compositions and methods described herein have an amino acid
sequence as set forth in SEQ ID NOS:6, 8, 10, 12, 14, 16, 18, 20,
22, 56, 58, 60, 62, 64, 66, 68 or 70, more preferably SEQ ID NO:6,
SEQ ID NO:56 or SEQ ID NO:58.
[0077] The present description also pertains to methods for
reducing the risk of an immunopathological response associated with
RSV infection, comprising administering to a subject in need
thereof a composition comprising at least one respiratory syncytial
virus G protein immunogen or fragment thereof comprising an amino
acid sequence that is at least 80% identical to SEQ ID NO: 2,
wherein the G protein immunogen has an epitope that elicits a
protective immune response without eliciting an immunopathological
response or with a reduced immunopathological response, and
pharmaceutically acceptable carrier, diluent, or excipient, at a
dose sufficient to elicit an immune response specific for one or
more G protein immunogen or fragment thereof. In certain
embodiments, an infection is due to a subgroup A, subgroup B, or
both subgroups A and B of RSV. In certain preferred embodiments,
the G protein immunogens used in any of the compositions and
methods described herein have an amino acid sequence as set forth
in SEQ ID NOS:6, 8, 10, 12, 14, 16, 18, 20, 22, 56, 58, 60, 62, 64,
66, 68 or 70, more preferably SEQ ID NO:6, SEQ ID NO:56 or SEQ ID
NO:58.
[0078] A subject suitable for treatment with a RSV immunogen
formulation may be identified by well-established indicators of
risk for developing a disease or well-established hallmarks of an
existing disease. For example, indicators of an infection include
fever, pus, microorganism positive cultures, inflammation, and the
like. Infections that may be treated or prevented with a RSV
immunogen vaccine of the subject invention include those caused by
or due to RSV, whether the infection is primary, secondary,
opportunistic, or the like. Examples of RSV include any subtype,
strain, antigenic variant, and the like, of these viruses. For
preventative purposes, for example, certain known risk factors for
acquiring an RSV infection include premature birth, children with
chronic lung disease, children that attend daycare, presence of
school-age siblings in the home, exposure to passive smoke in the
home, and immunocompromised subjects (adult and children).
[0079] Pharmaceutical compositions containing one or more RSV
immunogens of the instant description may be in any form that
allows the composition to be administered to a subject, such as a
human or animal. For example, G protein immunogen, fusion protein,
and multivalent compositions of the present description may be
prepared and administered as a liquid solution or prepared as a
solid form (e.g., lyophilized), which may be administered in solid
form, or resuspended in a solution in conjunction with
administration. The hybrid polypeptide composition is formulated so
as to allow the active ingredients contained therein to be
bioavailable upon administration of the composition to a subject or
patient or bioavailable via slow release. Compositions that will be
administered to a subject or patient take the form of one or more
dosage units, where for example, a tablet may be a single dosage
unit, and a container of one or more compounds of the invention in
aerosol form may hold a plurality of dosage units. In certain
preferred embodiments, any of the herein described pharmaceutical
compositions comprising a RSV immunogen or cocktail of immunogens
of the invention are in a container, preferably in a sterile
container.
[0080] In one embodiment, the therapeutic composition is
administered nasally, wherein cells, such as cells located in the
nasal associated lymphoid tissue, can take up an RSV immunogen or
cocktail composition of this disclosure. Other typical routes of
administration include, without limitation, enteral, parenteral,
transdermal/transmucosal, nasal, and inhalation. The term
"enteral", as used herein, is a route of administration in which
the immunogenic composition is absorbed through the
gastrointestinal tract or oral mucosa, including oral, rectal, and
sublingual. The term "parenteral", as used herein, describes
administration routes that bypass the gastrointestinal tract,
including intraarterial, intradermal, intramuscular, intranasal,
intraocular, intraperitoneal, intravenous, subcutaneous,
submucosal, and intravaginal injection or infusion techniques. The
term "transdermal/transmucosal", as used herein, is a route of
administration in which the immunogenic composition is administered
through or by way of the skin, including topical. The terms "nasal"
and "inhalation" encompass techniques of administration in which an
immunogenic composition is introduced into the pulmonary tree,
including intrapulmonary or transpulmonary. Preferably, the
compositions of the present invention are administered nasally.
[0081] In another embodiment, the instant compositions comprising
at least one respiratory syncytial virus G protein immunogen or
fragment thereof can be used in prophylactic methods. For example,
an RSV immunogen or cocktail composition of the invention may be
administered to a mother during gestation to prevent an RSV
infection in the mother and to provide passive immunity to the
fetus or new born. A prophylactic method may comprise administering
to a first subject a composition comprising an RSV immunogen and
pharmaceutically acceptable carrier, diluent or excipient, followed
by administration to a second subject of a second composition
comprising at least one respiratory syncytial virus immunogen
wherein said first composition comprises a different RSV immunogen
than that administered to the second subject and the second
composition comprises at least one respiratory syncytial virus G
protein immunogen or fragment thereof comprising an amino acid
sequence that is at least 80% identical to SEQ ID NO: 2 and a
pharmaceutically acceptable carrier, diluent or excipient, wherein
the G protein immunogen has an epitope that elicits a protective
immune response without eliciting an, or with a reduced,
immunopathological response. In certain embodiments, the G protein
immunogens for prophylactic use can have an amino acid sequence as
set forth in SEQ ID NOS:6, 8, 10, 12, 14, 16, 18, 20, 22, 56, 58,
60, 62, 64, 66, 68 or 70, more preferably SEQ ID NO:6, SEQ ID NO:56
or SEQ ID NO:58.
[0082] A representative first subject can be a mother during
gestation and a representative second subject can be the mother's
newborn child. Each composition is provided at a dose sufficient to
elicit an immune response specific for one or more RSV immunogen
(such as G protein immunogens described herein). For instance, not
wishing to be bound by theory, G protein immunogens and
compositions thereof can be administered systemically (e.g.,
intravenously) to the mother, which would elicit IgG antibodies
similar to the antibodies the mother already has due to exposure to
RSV. The newborn child can then be immunized via the mucosa (e.g.,
intranasally), which would elicit secretory IgA antibodies--hence,
the G protein immunogens administered via the mucosa will not be
detected by the systemic maternal (IgG) antibodies the child
inherited because the IgG antibodies will not be at the mucosal
interface. That is, the maternally inherited antibodies will not
adversely affect the IgA response elicited by intranasal
immunization of the child. In certain embodiments, the administered
compositions may prevent an infection due to a subgroup A, subgroup
B, or both subgroups A and B of RSV. A subject suitable for
treatment with a RSV immunogen formulation may be identified by
well-established indicators of risk for developing a disease or
well-established hallmarks of an existing disease as described
herein and is known in the art. Infections that may be treated with
a RSV immunogen of the subject invention include those caused by or
due to RSV, whether the infection is primary, secondary,
opportunistic, or the like. Examples of RSV include any strain,
subtype, antigenic variant, and the like of these viruses.
[0083] The invention further provides a plurality of antibodies
produced by the method for preventing a RSV infection that
comprises administering to a subject a composition of the subject
invention at a dose sufficient to elicit antibodies specific for
one or more RSV immunogen wherein said G protein immunogen has an
epitope that elicits a protective immune response without eliciting
an, or with a reduced, immunopathological response. In one
embodiment, the antibodies comprise at least one antibody specific
for a subgroup A RSV, or a subgroup B RSV, or for both subgroup A
and B RSVs. In another embodiment, a method for treating or
preventing a RSV infection comprises administering to a subject a
composition comprising a pharmaceutically acceptable carrier, with
or without an adjuvant, and a plurality of antibodies of the
subject invention.
[0084] In addition, a subject at risk for an RSV infection can have
a plurality of antibodies according to this description
administered before, simultaneous with, or after administration of
a composition comprising at least one different respiratory
syncytial virus G protein immunogen or fragment thereof comprising
an amino acid sequence that is at least 80% identical to SEQ ID NO:
2 and pharmaceutically acceptable carrier, diluent or excipient,
according to the instant description. In certain preferred
embodiments, the G protein immunogens used in any of the
compositions and methods described herein have an amino acid
sequence as set forth in SEQ ID NOS:6, 8, 10, 12, 14, 16, 18, 20,
22, 56, 58, 60, 62, 64, 66, 68 or 70, more preferably SEQ ID NO:6,
SEQ ID NO:56 or SEQ ID NO:58. In some embodiments, antibodies
specific for one or more RSV immunogens can be provided passively,
while the subject is vaccinated to actively elicit antibodies
against one or more different RSV immunogens.
[0085] In another aspect, the RSV G protein immunogens and
fragments, variants thereof of the present invention are utilized
to elicit antibodies specific for at least one epitope present on
the G protein immunogens and fragments or variants thereof provided
herein. Accordingly, the present invention also provides such
antibodies. In preferred embodiments the antibodies bind to
specific protective epitopes present on an RSV G protein. Within
the context of the present invention, the term "antibodies"
includes polyclonal antibodies, monospecific antibodies, monoclonal
antibodies, anti-idiotypic antibodies, fragments thereof such as
F(ab').sub.2 and Fab fragments, and recombinantly or synthetically
produced antibodies. Such antibodies incorporate the variable
regions that permit a monoclonal antibody to specifically bind,
which means an antibody is able to selectively bind to a peptide or
polypeptide from an RSV G protein from subtype A or B. "Specific
for" refers to the ability of a protein (e.g., an antibody) to
selectively bind a polypeptide or peptide encoded by a nucleic acid
molecule encoding a from an RSV G protein from subtype A or B, or a
synthesized RSV G protein from subtype A or B, of this invention.
Association or "binding" of an antibody to a specific antigen
generally involve electrostatic interactions, hydrogen bonding, Van
der Waals interactions, and hydrophobic interactions. Any one of
these or any combination thereof can play a role in the binding
between an antibody and its antigen. Such an antibody generally
associates with an antigen, such as a G protein immunogen, with an
affinity constant (K.sub.a) of at least 10.sup.4, preferably at
least 10.sup.5, more preferably at least 10.sup.6, still more
preferably at least 10.sup.7 and most preferably at least 10.sup.8.
Affinity constants may be determined by one of ordinary skill in
the art using well-known techniques (see Scatchard, Ann. N.Y. Acad.
Sci. 51:660-672, 1949). The affinity of a monoclonal antibody or
antibody can be readily determined by one of ordinary skill in the
art (see Scatchard, Ann. N.Y. Acad. Sci. 51:660-672, 1949).
[0086] In addition, the term "antibody," as used herein, includes
naturally occurring antibodies as well as non-naturally occurring
antibodies, including, for example, single chain antibodies,
chimeric, bifunctional and humanized antibodies, fully human
antibodies, as well as antigen-binding fragments thereof. Such
non-naturally occurring antibodies may be constructed using solid
phase peptide synthesis, may be produced recombinantly, or may be
obtained, for example, by screening combinatorial libraries
consisting of variable heavy chains and variable light chains (Huse
et al., Science 246:1275-1281 (1989)). These and other methods of
making, for example, chimeric, humanized, CDR-grafted, single
chain, and bifunctional antibodies are well known in the art
(Winter and Harris, Immunol. Today 14:243, 1993; Ward et al.,
Nature 341:544, 1989; Harlow and Lane, Antibodies: A Laboratory
Manual, Cold Spring Harbor Laboratory, New York, 1992; Borrabeck,
Antibody Engineering, 2d ed., Oxford Univ. Press, 1995; Hilyard et
al., Protein Engineering: A practical approach, IRL Press,
1992).
[0087] Polyclonal antibodies can be readily generated by one of
ordinary skill in the art from a variety of warm-blooded animals,
including horses, cows, goats, sheep, dogs, chickens, turkeys,
rabbits, mice, or rats. Briefly, the desired G protein immunogen or
fragment thereof, or mixtures of RSV immunogens, or variants
thereof are administered to immunize an animal through parenteral,
intraperitoneal, intramuscular, intraocular, or subcutaneous
injections. The immunogenicity of the hybrid polypeptide of
interest may be increased through the use of an adjuvant, such as
alum and Freund's complete or incomplete adjuvant. Following
several booster immunizations over a period of weeks, small samples
of serum are collected and tested for reactivity to the desired
immunogen. Once the titer of the animal has reached a plateau in
terms of its reactivity to a G protein immunogen of the invention,
larger quantities of polyclonal immune sera may be readily obtained
either by weekly bleedings or by exsanguinating the animal.
[0088] The RSV immunogens of the instant invention can be easily
identified using in vitro and in vivo assays known in the art and
as described herein. Representative assays are described in the
Examples. Similarly, several assays are available as described
herein to examine the activity of the antibodies elicited by the
RSV immunogens of the subject invention.
[0089] All of the U.S. patents, U.S. patent application
publications, U.S. patent applications, foreign patents, foreign
patent applications and non-patent publications referred to in this
specification or listed in the Application Data Sheet, are
incorporated herein by reference, in their entirety. The invention
having been described, the following examples are intended to
illustrate, and not limit, the invention.
EXAMPLES
Example 1
Preparation of Proteosomes
[0090] Immunogens of the instant invention may be formulated with
proteosomes by way of non-covalent interactions to form a vaccine
composition capable of eliciting a protective immune response in an
immunized human or animal subject. Proteosomes of the instant
application are mucosal adjuvant delivery vehicles comprising outer
membrane proteins purified from, for example, Group B type 2
Neisseria meningitides. The use of proteosomes for the formulation
of vaccines has been reviewed by Lowell, G. H., in "New Generation
Vaccines 2.sup.nd ed., Marcel Dekker, Inc., New York, Basil, Hong
Kong (1997) pages 193-206. Proteosomes of the instant invention may
be prepared by extraction of phenol-killed bacterial paste with a
solution of 6% Empigen BB (EBB) (Albright and Wilson, Whithaven,
UK) in 1 M calcium chloride followed by precipitation with ethanol,
solubilization in 1% EBB-Tris/EDTA-saline and then precipitation
with ammonium sulfate. The precipitates are re-solubilized in the
1% EBB buffer, dialyzed, and stored in 0.1% EBB at -70.degree. C.
Alternative processes may be used in the preparation of
proteosomes, for example, proteosomes may be prepared by omitting
the ammonium sulfate precipitation step to shorten the process.
Preparation of proteosomes are disclosed in U.S. Patent Application
Publication No. 2001/0053368 and in U.S. Pat. No. 6,476,201 B1.
Example 2
Preparation of Liposomes
[0091] Immunogens of the instant invention may be combined
non-covalently with liposomes as a vaccine composition capable of
eliciting a protective immune response in an immunized human or
animal subject. Immunogens may be encapsulated with multilamellar
liposomes according to procedures known to those of ordinary skill
in the art using, for example, a dehydration coupled reconstitution
method (Kirby and Gregoriadis, BioTechnology 2:979, 1984). Briefly,
liposomes are prepared by sonication of dioleoylphosphatidyl
choline (DOPC/cholesterol, Sigma Chemical Co., St. Louis, Mo.; 5:1,
W/W) at a final lipid concentration of 30 mg/ml in PBS or
generating liposomes using Deinococcus radiodurans lipids or
.alpha.-galactosylphosphotidylglycerolalkylamine as described in
Huang and Anderson, Vaccine 20:1586, 2002, in the presence or
absence of antigen. The liposome, with or without one or more
immunogens, are lyophilized and resuspended in sterile water.
Immunogen that is not incorporated into liposomes may be removed by
repeated washing and centrigugation (e.g., microcentrifugation for
1 min at 13,200 rpm) of the liposomes in phosphate buffered saline
(PBS). The protein content of washed liposomes, with and without
immunogen, is determined by, for example, quantitative
silver-stained SDS-PAGE using calibrated amounts known protein
standards, such as serum albumin. The protein content of the
liposomes is determined and adjusted as desired, for example, the
protein content may be adjusted to 0.3 mg per mg of lipid (as
liposomes) per ml.
[0092] In some cases, to evaluate the manner in which the protein
antigen interacts with a liposome, liposomes containing aliquots of
G protein immunogens and fragments thereof (wild type or mutant)
may be incubated for 1 hour at 37.degree. C. in PBS with proteinase
K (Gibco/BRL) at 1.0, 0.1 and 0.01 .mu.g/ml. Some incubations may
also contain 1% Triton X-100 to disrupt liposomes, thereby allowing
complete access of the proteinase K to the proteins, fusion
proteins, or polypeptide fragments thereof. Incubations are
terminated and samples analyzed by SDS-PAGE and silver staining.
Such procedures may be used to determine the extent of liposome
encapsulation of the immunogen (e.g., one or more viral proteins)
preparation.
Example 3
Preparation of Nucleic Acids and Expression Constructs Encoding G
Protein Immunogens and Fragments Thereof
[0093] G protein encoding nucleic acid sequences from the RSV (Long
strain) corresponding to amino acids 128-229, as well as, for
example, mutant 128-229 sequences were amplified from viral RNA by
RT-PCR, and the resultant PCR products cloned into the EcoRI and
XhoI sites of a pET-32-LIC bacterial expression plasmid (Novagen,
Madison, Wis.). Site-directed mutagenesis of the RSV G128-229
protein sequence was performed according to the Stratagene
QuikChange.RTM. site-directed mutagenesis protocol. Briefly, PCR
was performed on template pET-32-LIC-G128-229 DNA (G128-229
sequence cloned into EcoRI and XhoI sites).
[0094] In these experiments, the primer pairs designed for
mutagenesis were as follows:
TABLE-US-00001 (SEQ ID NO: 37)
CCTGCTGGGCTGCCTGCAAAAGAATACCAAACAAAAAACCAGG and (SEQ ID NO: 38)
CCTGGTTTTTTGTTTGGTATTCTTTTGCAGGCAGCCCAGC AGG (for the G128-229,
1185A mutant); (SEQ ID NO: 39)
CTGCTGGGCTATCGCCAAAAGAATACCAAACAAAAAACCAGG and (SEQ ID NO: 40)
CCTGGTTTTTTGTTTGGTATTCTTTTGGCGATAGCCCAGCAG (for the G128-229, C186A
mutant); (SEQ ID NO: 41) CTGCTGGGCTATCTGCGCAAGAATACCAAACAAAAAACCAGG
and (SEQ ID NO: 42) CCTGGTTTTTTGTTTGGTATTCTTGCGCAGATAGCCCAGCAG (for
the G128-229, K187A mutant); (SEQ ID NO: 43)
CTGCTGGGCTATCTGCAAAGCAATACCAAACAAAAAACCAGG and (SEQ ID NO: 44)
CCTGGTTTTTTGTTTGGTATTGCTTTGCAGATAGCCCAGCAG (for the G128-229, R188A
mutant); (SEQ ID NO: 45) CTGCTGGGCTATCTGCAAAAGAGCACCAAACAAAAAACCAGG
and (SEQ ID NO: 46) CCTGGTTTTTTGTTTGGTGCTCTTTTGCAGATAGCCCAGCAG (for
the G128-229, 1189A mutant); (SEQ ID NO: 47)
CTGCTGGGCTATCTGCAAAAGAATAGCAAACAAAAAACCAGG and (SEQ ID NO: 48)
CCTGGTTTTTTGTTTGCTATTCTTTTGCAGATAGCCCAGCAG (for the G128-229, P190A
mutant); (SEQ ID NO: 49)
CTGCAAAAGAATACCAGCCAAAAAACCAGGAAAGAAAACCACC and (SEQ ID NO: 50)
GGTGGTTTTCTTTCCTGGTTTTTTGGCTGGTATTCTTTTGCAG (for the G128-229,
N191A mutant); (SEQ ID NO: 51)
CTGGGCTATCTGCAAAAGAATACCAAACGCAAAACCAGGAAAG and (SEQ ID NO: 52)
CTTTCCTGGTTTTGCGTTTGGTATTCTTTTGCAGATAGCCCAG (for the G128-229,
K192A mutant); (SEQ ID NO: 53)
GCAAAAGAATACCAAACAAAGCACCAGGAAAGAAAACCACCAC and (SEQ ID NO: 54)
GTGGTGGTTTTCTTTCCTGGTGCTTTGTTTGGTATTCTTTTGC (for the G128-229,
K193A mutant).
[0095] Thioredoxin (Trx)-fusion proteins containing wild type, and
the above mutant RSV G protein fragments were prepared as described
in Example 4.
Example 4
Production of G Protein Immunogens and Fragments Thereof
[0096] RSV G protein immunogens can be prepared as pharmaceutical
compositions by mixing with a pharmaceutically acceptable carrier,
excipient or diluent. For example, the RSV G protein sequences
described herein and encoded by nucleic acid contained in modified
pET-32-LIC plasmids were expressed as thioredoxin (Trx)-fusion
proteins in transformed E. coli BL21/DE3 cells following induction
with IPTG. All Trx-fusion proteins were recovered from transformed
cell pellets by extraction with 8M urea, followed by affinity
purification using TALON.RTM. (Clontech, Palo Alto, Calif.) and
dialysis against PBS. Purified Trx-G128-229 polypeptides were freed
from contaminating endotoxin by treatment with polymyxin B beads
(BioRad, Mississauga, ON, Canada). Details and modifications of
this procedure are well known to those of ordinary skill in the
art. Upon use for immunization, immunogens can be further combined
or admixed with an adjuvant, such as alum or a proteosome-based
adjuvant.
Example 5
Preparation of RSV
[0097] RSV (Long strain) was obtained from the American Type
Culture Collection and propagated on HEp-2 cells cultured in
Earle's Minimal Essential Medium (MEM) containing penicillin G (100
U/ml) and streptomycin sulfate (100 ug/ml) and supplemented with 1%
serum (fetal calf serum/calf serum, 1:3). Cells and virus were
verified negative for mycoplama contamination by PCR assay
(American Type Culture Collection). As described in this Example,
confluent monolayer cultures of HEp-2 cells were inoculated with
RSV (Long strain) at a multiplicity of infection (MOI) of 1,
adsorbed 90 min at 4.degree. C., washed and incubated at 37.degree.
C. in RPMI-1640 medium (Sigma, St. Louis, Mo.) supplemented with 1%
fetal calf serum (Sigma, St. Louis, Mo.). Cultures were harvested
after 24-30 h, at which time the cell monolayers were almost
completely fused; virus was released from cells by disruption with
a hand-held Teflon scraper (Gibco-BRL) and cellular debris was
removed by microcentrifugation for 5 min at 13,000.times.g. The
supernatant was used as the source of virus for mouse challenge
studies (see Example 6).
Example 6
Mouse Immunization
[0098] All immunizations were performed using BALB/c mice (Charles
River, Step. Constance, QC, Canada), which were anaesthetized with
ketamine (2.3 mg/mouse; Bimeda-MTC Pharmaceuticals, Cambridge, ON,
Canada) and xylazine (0.5 mg/mouse; Bayer, Toronto, ON, Canada).
For vaccine/challenge experiments, groups of seven to nine BALB/c
mice (6-8 wks old) were immunized twice subcutaneously, at 14-day
intervals, with PBS/alum, Trx-G128-229, or mutant Trx-G128-229
proteins, in PBS/alum (10 .mu.g protein in a volume of 50 .mu.l).
Fourteen days after the second dose, mice were challenged
intranasally with RSV (2.times.10.sup.6 pfu in 50 .mu.l). Mice were
sacrificed using sodium pentobarbital four days later and assayed
for lung virus titers and leukocyte infiltration in bronchoalveolar
fluids according to procedures well known to a person of ordinary
skill in the art.
[0099] Immunoblot analysis demonstrated that serum antibodies
raised against amino acids 128-229 of RSV G protein were capable of
specifically recognizing RSV G protein in mice immunized with wild
type or mutant Trx-G128-229 proteins (FIG. 1). Extracts of
RSV-infected HEp-2 cells were resolved by SDS-PAGE, and transferred
to membranes (e.g., polyvinyldene difluoride (PVDF) membranes).
Membranes containing transferred protein were blocked (to prevent
non-specific interactions) with 4% skim milk and 0.5% casein
(Hammerstein grade) in TBST (0.8% NaCl, 0.1% Tween-20, 20 mM Tris,
pH 7.6) by overnight incubation at room temperature. Blocked
membranes were then incubated with serum samples, washed with TBST,
followed by 1 hour incubation with horse-radish peroxidase
(HRP)-conjugated goat antimouse antibody, and then signal was then
detected using diaminobezidine (DAB; 1 mg/ml, 0.03% NiCl2 and 0.1%
H2O2, according to procedures known in the art. A strong G
protein-specific antibody (IgG) response was observed with wild
type and N191A mutant proteins. Very little RSV G protein antibody
specific signal was observed in sera obtained from mice immunized
with I185A or K187A mutant RSV G polypeptide fusion proteins. The
remaining Trx-G128-229 mutant proteins induced intermediate levels
of RSV G-specific antibodies (FIG. 1).
Example 7
RSV Challenge of Immunized Mice
[0100] In these experiments, mice were immunized (as described in
Example 6) with either wild type Trx-G128-229 or one of each of the
9 mutants and then challenged with RSV. Induction of eosinophilia
was determined according to procedures described in Mader et al.
Vaccine 18:1110, 2000. As shown in FIG. 2A, wild type Trx-G128-229
and various single mutants protected mice against RSV challenge to
varying degrees. Comparatively, the N191A mutated Trx-G128-229
provided better protection than did mutants P190A, R188A and 189A.
The remaining Trx-G128-229 mutant proteins conferred intermediate
levels of protection. Furthermore, comparatively, the R188A and
N191A mutants demonstrated the highest level of protection. This
surprising result indicates that a single point mutation in a G
protein can result in a polypeptide capable of eliciting a
protective immune response concomitantly with a much reduced
immunopathological response (e.g., pulmonary eosinophilia).
Example 8
RSV Neutralization Assay
[0101] In these experiments, aliquots of pre-titered RSV were mixed
with serially diluted samples of individual mouse sera and
incubated for 1 hr at room temperature. Serum from individual mice
was collected 14 days after the second of two subcutaneous
administrations of an immunogen in alum, as described in Example 6.
Sera were assayed for RSV neutralizing antibodies by plaque
reduction assay. Mixtures were applied in duplicate to 24-well
plates containing 60-80% confluent monolayers of HEp-2 cells,
adsorbed for 90 minutes at 4.degree. C., followed by washing and
incubation of the plates for 40 h at 37.degree. C. in 1 ml of RPMI
medium supplemented with 1% fetal calf serum. After incubation, the
monolayers were fixed with 15% formaldehyde and stained with 0.01%
crystal violet for visualization of viral plaques. Plaque reduction
is calculated as the plaque reduction neutralization titer.sub.50
(PRNT.sub.50), which is the reciprocal dilution of sera required to
neutralize 50% of RSV plaques on a sub-confluent monolayer of HEp-2
cells.
[0102] Results of an RSV plaque reduction assay are shown in Table
1. The RSV neutralization titers in sera from immunized mice showed
a strong dependence of neutralizing antibody responses upon the
amino acid sequence within the 185-193 region of the Trx-G128-229
protein used for immunization (similar to the immunization results
of Example 6).
TABLE-US-00002 TABLE 1 Neutralization titers of sera from mice
immunized with Trx-G variant proteins Immunogen PRNT.sub.50* PBS 7
.+-. 3 Trx-G128-229 144 .+-. 37 Trx-G128-229 (I185A) 18 .+-. 5
Trx-G128-229 (C186A) 81 .+-. 12 Trx-G128-229 (K187A) 34 .+-. 11
Trx-G128-229 (R188A) 39 .+-. 13 Trx-G128-229 (I189A) 115 .+-. 38
Trx-G128-229 (P190A) 98 .+-. 26 Trx-G128-229 (N191A) 95 .+-. 21
Trx-G128-229 (K192A) 27 .+-. 7 Trx-G128-229 (K193A) 31 .+-. 12
*PRNT.sub.50 (Plaque Reduction Neutralization Titer.sub.50) is
calculated by determining the reciprocal dilution of sera required
to neutralize 50% of RSV plaques on HEp-2 cells. The results are
expressed as a mean .+-. SD.
Example 9
[0103] Response of Cytokine mRNA to RSV G Protein Variants
[0104] Cytokine mRNA levels in lungs of mice immunized with various
RSV G protein variants were measured using a ribonuclease
protection assay, which can be an indicator of whether a harmful
eosinophilic response will result. One lobe from each mouse lung
was stored at -20.degree. C. in RNAlater.TM. solution (Qiagen,
Mississauga, ON, Canada) and subsequently processed for RNA
extraction using the RNeasy.RTM. mini kit (Qiagen, Mississauga, ON,
Canada). RNA was quantitated and subjected to ribonuclease
protection assay (RPA) using a transcription kit (BD-Pharmingen,
Mississauga, ON, Canada) to synthesize probe from a cytokine
(MCK-1) template (BD-Pharmingen, Mississauga, ON, Canada),
radiolabeled using .alpha.-.sup.32P [UTP] and followed by
hybridization and RNase digestion using an RPAIII kit (Ambion,
Austin, Tex.). Reaction mixtures were resolved on a 5%
polyacrylamide 8M urea gel according to the manufacturer's
instructions followed by drying and autoradiography at -70.degree.
C. using an intensifying screen.
[0105] The RPA results illustrated striking differences among the
mice immunized with wild-type or mutant Trx-G proteins and
subsequently challenged with RSV (FIG. 4). As shown in FIG. 4, the
Th2 type cytokines most prone to upregulation were IL-4, IL-10,
IL-13 and, to a lesser extent, IL-5. G protein variants K193A,
P190A and I189A were found to provoke dramatic IL-4, IL-10 and
IL-13 responses. Weak IL-4, IL-10 and IL-13 responses were observed
with other G protein variants, such as N192A, N191A, R188A, K187A
and C186A. The results of the present study highlight the apparent
importance of IL-13, which has been recently implicated in asthma
(Grunig et al., Science 282: 2261, 1998) as well as in RSV
vaccine-induced disease (Johnson and Graham, J. Virol. 73:8485,
1999). High levels of IL-13 and IL-10 correlated well with high
levels of eosinophilia observed in RSV-challenged mice that had
been immunized with wild type or mutants I189A, P190A, K192A and
K193A. In contrast, mutants such as N191A, K187A and R188A were
poor inducers of IL-13, IL-10 and eosinophilia, despite being
decent inducers of IL-4.
[0106] In comparison, the prototype Th1 cytokine, IFN-.gamma., was
elevated in all experimental mouse groups. By way of example and
not wishing to be bound by theory, this may reflect the expression
of IFN-.gamma. from NK cells as well as Th1 cells (Trinchieri, Adv.
Immunol. 47:187, 1989), the rapid induction of IFN-.gamma. upon RSV
infection (Hussell and Openshaw, J. Gen. Virol. 79: 2593, 1998),
and/or the prevalent nature of IFN-.gamma. expression even in
immune processes in which a Th2 response appears to predominate
(Waris et al., J. Virol. 70:2852, 1996; Spender et al., J. Gen.
Virol. 79: 1751, 1998; Srikiatkhachom and Braciale, J. Virol. 71:
678, 1997).
Example 10
[0107] Preparation of Proteosomes Containing RSV G Protein
Immunogens
[0108] Portions of stock RSV G protein product immunogens (e.g.,
wild type or mutant peptides) may be formulated with proteosomes
using, by way of example, diafiltration/ultrafiltration methods or
by using dialysis. For either method, the RSV G protein product is
dissolved in, for example, a saline buffered solution containing
the desired detergent (e.g., Empigen BB (EBB) at 1% or, at 0.1%-2%
of EBB or other suitable detergent depending on the type of
detergent used) and is then mixed with proteosomes in saline
buffered 1% Empigen solution (or other appropriate detergent at
appropriate concentrations) at various proteosome:RSV G (wt/wt)
ratios ranging from 1:4 to 8:1, including 1:4, 1:1, 2:1, 4:1 and
8:1. To remove Empigen, the mixture may then be subjected to
ultrafiltration/diafilt-ration technology or is exhaustively
dialyzed across a dialysis membrane with, for example, a 10,000
molecular weight cut-off (MWCO) or functionally similar membranes
with MWCO ranges of 1,000-30,000 against buffered saline for 1-2
weeks at 4.degree. C. exchanging at least 500 parts buffer each
day. At various steps, immunological assays such as ELISA and
single radial immunodiffusion (SRID) may be used to measure
potency. The halo immunodiffusion technique is used to determine
the content of formulate RSV G antigen with proteosomes at various
ratios (for details on the preparation of proteosomes, see, e.g.,
U.S. Patent Application Publication No. 2001/0053368).
[0109] Multivalent vaccines may also be prepared by making
individual monovalent proteosome vaccines and then combining them
at the required proportions prior to final formulation and fill.
Multivalent preparations may also be formulated by pooling
individual RSV G antigens in the desired proportions and
formulating the mixture with proteosomes. Multivalent vaccine
preparations may contain one or more RSV F protein immunogens
and/or one or more M protein immunogens in combination with one or
more RSV G protein immunogens. The vaccine composition is then
passed through membrane filters of 0.8 .mu.m pore size and stored
at 4.degree. C. prior to and during immunizations.
[0110] RSV G protein immunogens (e.g., wild type or mutant peptides
in any of the previous forms) may also be formulated with various
amounts of proteosome-LPS adjuvant as disclosed in, for example,
U.S. Pat. No. 6,476,201 B1, and described herein.
Example 11
Immunization with Protollin Formulated RSV G Protein Immunogens
[0111] Mice were immunized intranasally with RSV G wild-type (amino
acids 128-229) or the mutant (N191A) proteins formulated with
Protollin to determine whether RSV-specific systemic and mucosal
titers were elicited. BALB/c mice were immunized three times with a
dose of 6 .mu.g or 2 .mu.g of either the Trx-(polyHis)-G(128-229)
fusion proteins alone, or adjuvanted with protollin or alum.
Protollin alone or fusion proteins formulated with protollin were
administered intranasally, and alum alone or fusion proteins
formulated with alum were administered subcutaneously. Blood was
drawn from the saphenous vein after the second dose (day 35) and
serum was obtained by exsanguination two weeks after the third dose
(day 62). Bronchoalveolar lavage (BAL) samples were also collected
on day 62.
[0112] RSV G-specific serum IgG and BAL IgA titers were determined
by ELISA. A 10-fold increase in serum IgG titers was observed in
mice immunized intranasally with Trx-(polyHis)-G(128-229)
formulated with Protollin compared to mice immunized with
Trx-(polyHis)-G(128-229) alone, at both the 6 and 2 .mu.g doses
(FIG. 5). There was no significant difference in serum IgG titers
between the groups immunized intranasally with Protollin
formulations or subcutaneously with alum formulations. Comparable
titers were obtained for both G(128-229) wild-type and G(128-229)
mutant N191A when given with either adjuvant. RSV
G(128-229)-specific BAL IgA titers were significantly higher in the
groups having received the G(128-229) immunogens (wild-type or
mutant) formulated with Protollin compared to the groups immunized
with the immunogens alone (FIG. 6). Again, comparable titers were
obtained for both wild-type and mutant G(128-229) immunogens. As
expected, no IgA was detected in the groups immunized
subcutaneously with the G(128-229) immunogens formulated with alum.
These results indicate the Protollin formulated G(128-229)
immunogens (wild-type or mutant) vaccines are well tolerated and
are immunogenic when administered intranasally.
[0113] From the foregoing it will be appreciated that, although
specific embodiments of the invention have been described herein
for purposes of illustration, various modifications may be made
without deviating from the spirit and scope of the invention.
Accordingly, the invention is not limited except as by the appended
claims.
Sequence CWU 1
1
721917DNAArtificial SequenceRSV mutant sequence 1ggggcaaang
caaacatgtc caaaaacaag gaccaacgca ccgctaagac actagaaaag 60acctgggaca
ctctcaatca tttattattc atatcatcgg gcttatataa gttaaatctt
120aaatctatag cacaaatcac attatccatt ctggcaatga taatctcaac
ttcacttata 180attacagcca tcatattcat agcctcggca aaccacaaag
tcacactaac aactgcaatc 240atacaagatg caacaagcca gatcaagaac
acaaccccaa catacctcac tcaggatcct 300cagcttggaa tcagcttctc
caatctgtct gaaattacat cacaaaccac caccatacta 360gcttcaacaa
caccaggagt caagtcaaac ctgcaaccca caacagtcaa gactaaaaac
420acaacaacaa cccaaacaca acccagcaag cccactacaa aacaacgcca
aaacaaacca 480ccaaacaaac ccaataatga ttttcacttc gaagtgttta
actttgtacc ctgcagcata 540tgcagcaaca atccaacctg ctgggctatc
tgcaaaagaa taccagccaa aaaaccagga 600aagaaaacca ccaccaagcc
tacaaaaaaa ccaaccttca agacaaccaa aaaagatcac 660aaacctcaaa
ccactaaacc aaaggaagta cccaccacca agcccacaga agagccaacc
720atcaacacca ccaaaacaaa catcataact acactactca ccaacaacac
cacaggaaat 780ccaaaactca caagtcaaat ggaaaccttc cactcaacct
cctccgaagg caatctaagc 840ccttctcaag tctccacaac atccgagcac
ccatcacaac cctcatctcc acccaacaca 900acacgccagt agttatt
9172298PRTArtificial SequenceRSV mutant sequence 2Met Ser Lys Asn
Lys Asp Gln Arg Thr Ala Lys Thr Leu Glu Lys Thr 1 5 10 15Trp Asp
Thr Leu Asn His Leu Leu Phe Ile Ser Ser Gly Leu Tyr Lys 20 25 30Leu
Asn Leu Lys Ser Ile Ala Gln Ile Thr Leu Ser Ile Leu Ala Met 35 40
45Ile Ile Ser Thr Ser Leu Ile Ile Thr Ala Ile Ile Phe Ile Ala Ser
50 55 60Ala Asn His Lys Val Thr Leu Thr Thr Ala Ile Ile Gln Asp Ala
Thr65 70 75 80Ser Gln Ile Lys Asn Thr Thr Pro Thr Tyr Leu Thr Gln
Asp Pro Gln 85 90 95Leu Gly Ile Ser Phe Ser Asn Leu Ser Glu Ile Thr
Ser Gln Thr Thr 100 105 110Thr Ile Leu Ala Ser Thr Thr Pro Gly Val
Lys Ser Asn Leu Gln Pro 115 120 125Thr Thr Val Lys Thr Lys Asn Thr
Thr Thr Thr Gln Thr Gln Pro Ser 130 135 140Lys Pro Thr Thr Lys Gln
Arg Gln Asn Lys Pro Pro Asn Lys Pro Asn145 150 155 160Asn Asp Phe
His Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys 165 170 175Ser
Asn Asn Pro Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Ala Lys 180 185
190Lys Pro Gly Lys Lys Thr Thr Thr Lys Pro Thr Lys Lys Pro Thr Phe
195 200 205Lys Thr Thr Lys Lys Asp His Lys Pro Gln Thr Thr Lys Pro
Lys Glu 210 215 220Val Pro Thr Thr Lys Pro Thr Glu Glu Pro Thr Ile
Asn Thr Thr Lys225 230 235 240Thr Asn Ile Ile Thr Thr Leu Leu Thr
Asn Asn Thr Thr Gly Asn Pro 245 250 255Lys Leu Thr Ser Gln Met Glu
Thr Phe His Ser Thr Ser Ser Glu Gly 260 265 270Asn Leu Ser Pro Ser
Gln Val Ser Thr Thr Ser Glu His Pro Ser Gln 275 280 285Pro Ser Ser
Pro Pro Asn Thr Thr Arg Gln 290 2953917DNARespiratory syncytial
virusmisc_feature9n = A,T,C or G 3ggggcaaang caaacatgtc caaaaacaag
gaccaacgca ccgctaagac actagaaaag 60acctgggaca ctctcaatca tttattattc
atatcatcgg gcttatataa gttaaatctt 120aaatctatag cacaaatcac
attatccatt ctggcaatga taatctcaac ttcacttata 180attacagcca
tcatattcat agcctcggca aaccacaaag tcacactaac aactgcaatc
240atacaagatg caacaagcca gatcaagaac acaaccccaa catacctcac
tcaggatcct 300cagcttggaa tcagcttctc caatctgtct gaaattacat
cacaaaccac caccatacta 360gcttcaacaa caccaggagt caagtcaaac
ctgcaaccca caacagtcaa gactaaaaac 420acaacaacaa cccaaacaca
acccagcaag cccactacaa aacaacgcca aaacaaacca 480ccaaacaaac
ccaataatga ttttcacttc gaagtgttta actttgtacc ctgcagcata
540tgcagcaaca atccaacctg ctgggctatc tgcaaaagaa taccaaacaa
aaaaccagga 600aagaaaacca ccaccaagcc tacaaaaaaa ccaaccttca
agacaaccaa aaaagatcac 660aaacctcaaa ccactaaacc aaaggaagta
cccaccacca agcccacaga agagccaacc 720atcaacacca ccaaaacaaa
catcataact acactactca ccaacaacac cacaggaaat 780ccaaaactca
caagtcaaat ggaaaccttc cactcaacct cctccgaagg caatctaagc
840ccttctcaag tctccacaac atccgagcac ccatcacaac cctcatctcc
acccaacaca 900acacgccagt agttatt 9174298PRTRespiratory sy 4Met Ser
Lys Asn Lys Asp Gln Arg Thr Ala Lys Thr Leu Glu Lys Thr 1 5 10
15Trp Asp Thr Leu Asn His Leu Leu Phe Ile Ser Ser Gly Leu Tyr Lys
20 25 30Leu Asn Leu Lys Ser Ile Ala Gln Ile Thr Leu Ser Ile Leu Ala
Met 35 40 45Ile Ile Ser Thr Ser Leu Ile Ile Thr Ala Ile Ile Phe Ile
Ala Ser 50 55 60Ala Asn His Lys Val Thr Leu Thr Thr Ala Ile Ile Gln
Asp Ala Thr65 70 75 80Ser Gln Ile Lys Asn Thr Thr Pro Thr Tyr Leu
Thr Gln Asp Pro Gln 85 90 95Leu Gly Ile Ser Phe Ser Asn Leu Ser Glu
Ile Thr Ser Gln Thr Thr 100 105 110Thr Ile Leu Ala Ser Thr Thr Pro
Gly Val Lys Ser Asn Leu Gln Pro 115 120 125Thr Thr Val Lys Thr Lys
Asn Thr Thr Thr Thr Gln Thr Gln Pro Ser 130 135 140Lys Pro Thr Thr
Lys Gln Arg Gln Asn Lys Pro Pro Asn Lys Pro Asn145 150 155 160Asn
Asp Phe His Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys 165 170
175Ser Asn Asn Pro Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys
180 185 190Lys Pro Gly Lys Lys Thr Thr Thr Lys Pro Thr Lys Lys Pro
Thr Phe 195 200 205Lys Thr Thr Lys Lys Asp His Lys Pro Gln Thr Thr
Lys Pro Lys Glu 210 215 220Val Pro Thr Thr Lys Pro Thr Glu Glu Pro
Thr Ile Asn Thr Thr Lys225 230 235 240Thr Asn Ile Ile Thr Thr Leu
Leu Thr Asn Asn Thr Thr Gly Asn Pro 245 250 255Lys Leu Thr Ser Gln
Met Glu Thr Phe His Ser Thr Ser Ser Glu Gly 260 265 270Asn Leu Ser
Pro Ser Gln Val Ser Thr Thr Ser Glu His Pro Ser Gln 275 280 285Pro
Ser Ser Pro Pro Asn Thr Thr Arg Gln 290 2955306DNAArtificial
SequenceRSV mutant fragment 5cccacaacag tcaagactaa aaacacaaca
acaacccaaa cacaacccag caagcccact 60acaaaacaac gccaaaacaa accaccaaac
aaacccaata atgattttca cttcgaagtg 120tttaactttg taccctgcag
catatgcagc aacaatccaa cctgctgggc tatctgcaaa 180agaataccag
ccaaaaaacc aggaaagaaa accaccacca agcctacaaa aaaaccaacc
240ttcaagacaa ccaaaaaaga tcacaaacct caaaccacta aaccaaagga
agtacccacc 300accaag 3066102PRTArtificial SequenceRSV mutant
fragment 6Pro Thr Thr Val Lys Thr Lys Asn Thr Thr Thr Thr Gln Thr
Gln Pro 1 5 10 15Ser Lys Pro Thr Thr Lys Gln Arg Gln Asn Lys Pro
Pro Asn Lys Pro 20 25 30Asn Asn Asp Phe His Phe Glu Val Phe Asn Phe
Val Pro Cys Ser Ile 35 40 45Cys Ser Asn Asn Pro Thr Cys Trp Ala Ile
Cys Lys Arg Ile Pro Ala 50 55 60Lys Lys Pro Gly Lys Lys Thr Thr Thr
Lys Pro Thr Lys Lys Pro Thr65 70 75 80Phe Lys Thr Thr Lys Lys Asp
His Lys Pro Gln Thr Thr Lys Pro Lys 85 90 95Glu Val Pro Thr Thr Lys
1007306DNAArtificial SequenceRSV mutant sequence 7cccacaacag
tcaagactaa aaacacaaca acaacccaaa cacaacccag caagcccact 60acaaaacaac
gccaaaacaa accaccaaac aaacccaata atgattttca cttcgaagtg
120tttaactttg taccctgcag catatgcagc aacaatccaa cctgctgggc
tatctgcaaa 180gcaataccaa acaaaaaacc aggaaagaaa accaccacca
agcctacaaa aaaaccaacc 240ttcaagacaa ccaaaaaaga tcacaaacct
caaaccacta aaccaaagga agtacccacc 300accaag 3068102PRTArtificial
SequenceRSV mutant fragment 8Pro Thr Thr Val Lys Thr Lys Asn Thr
Thr Thr Thr Gln Thr Gln Pro 1 5 10 15Ser Lys Pro Thr Thr Lys Gln
Arg Gln Asn Lys Pro Pro Asn Lys Pro 20 25 30Asn Asn Asp Phe His Phe
Glu Val Phe Asn Phe Val Pro Cys Ser Ile 35 40 45Cys Ser Asn Asn Pro
Thr Cys Trp Ala Ile Cys Lys Ala Ile Pro Asn 50 55 60Lys Lys Pro Gly
Lys Lys Thr Thr Thr Lys Pro Thr Lys Lys Pro Thr65 70 75 80Phe Lys
Thr Thr Lys Lys Asp His Lys Pro Gln Thr Thr Lys Pro Lys 85 90 95Glu
Val Pro Thr Thr Lys 1009306DNAArtificial SequenceRSV mutant
fragment 9cccacaacag tcaagactaa aaacacaaca acaacccaaa cacaacccag
caagcccact 60acaaaacaac gccaaaacaa accaccaaac aaacccaata atgattttca
cttcgaagtg 120tttaactttg taccctgcag catatgcagc aacaatccaa
cctgctgggc tatctgcaaa 180agaatagcaa acaaaaaacc aggaaagaaa
accaccacca agcctacaaa aaaaccaacc 240ttcaagacaa ccaaaaaaga
tcacaaacct caaaccacta aaccaaagga agtacccacc 300accaag
30610102PRTArtificial SequenceRSV mutant fragment 10Pro Thr Thr Val
Lys Thr Lys Asn Thr Thr Thr Thr Gln Thr Gln Pro 1 5 10 15Ser Lys
Pro Thr Thr Lys Gln Arg Gln Asn Lys Pro Pro Asn Lys Pro 20 25 30Asn
Asn Asp Phe His Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile 35 40
45Cys Ser Asn Asn Pro Thr Cys Trp Ala Ile Cys Lys Arg Ile Ala Asn
50 55 60Lys Lys Pro Gly Lys Lys Thr Thr Thr Lys Pro Thr Lys Lys Pro
Thr65 70 75 80Phe Lys Thr Thr Lys Lys Asp His Lys Pro Gln Thr Thr
Lys Pro Lys 85 90 95Glu Val Pro Thr Thr Lys 10011306DNAArtificial
SequenceRSV mutant fragment 11cccacaacag tcaagactaa aaacacaaca
acaacccaaa cacaacccag caagcccact 60acaaaacaac gccaaaacaa accaccaaac
aaacccaata atgattttca cttcgaagtg 120tttaactttg taccctgcag
catatgcagc aacaatccaa cctgctgggc tgcctgcaaa 180agaataccaa
acaaaaaacc aggaaagaaa accaccacca agcctacaaa aaaaccaacc
240ttcaagacaa ccaaaaaaga tcacaaacct caaaccacta aaccaaagga
agtacccacc 300accaag 30612102PRTArtificial SequenceRSV mutant
fragment 12Pro Thr Thr Val Lys Thr Lys Asn Thr Thr Thr Thr Gln Thr
Gln Pro 1 5 10 15Ser Lys Pro Thr Thr Lys Gln Arg Gln Asn Lys Pro
Pro Asn Lys Pro 20 25 30Asn Asn Asp Phe His Phe Glu Val Phe Asn Phe
Val Pro Cys Ser Ile 35 40 45Cys Ser Asn Asn Pro Thr Cys Trp Ala Ala
Cys Lys Arg Ile Pro Asn 50 55 60Lys Lys Pro Gly Lys Lys Thr Thr Thr
Lys Pro Thr Lys Lys Pro Thr65 70 75 80Phe Lys Thr Thr Lys Lys Asp
His Lys Pro Gln Thr Thr Lys Pro Lys 85 90 95Glu Val Pro Thr Thr Lys
10013306DNAArtificial SequenceRSV mutant fragment 13cccacaacag
tcaagactaa aaacacaaca acaacccaaa cacaacccag caagcccact 60acaaaacaac
gccaaaacaa accaccaaac aaacccaata atgattttca cttcgaagtg
120tttaactttg taccctgcag catatgcagc aacaatccaa cctgctgggc
tatcgccaaa 180agaataccaa acaaaaaacc aggaaagaaa accaccacca
agcctacaaa aaaaccaacc 240ttcaagacaa ccaaaaaaga tcacaaacct
caaaccacta aaccaaagga agtacccacc 300accaag 30614102PRTArtificial
SequenceRSV mutant fragment 14Pro Thr Thr Val Lys Thr Lys Asn Thr
Thr Thr Thr Gln Thr Gln Pro 1 5 10 15Ser Lys Pro Thr Thr Lys Gln
Arg Gln Asn Lys Pro Pro Asn Lys Pro 20 25 30Asn Asn Asp Phe His Phe
Glu Val Phe Asn Phe Val Pro Cys Ser Ile 35 40 45Cys Ser Asn Asn Pro
Thr Cys Trp Ala Ile Ala Lys Arg Ile Pro Asn 50 55 60Lys Lys Pro Gly
Lys Lys Thr Thr Thr Lys Pro Thr Lys Lys Pro Thr65 70 75 80Phe Lys
Thr Thr Lys Lys Asp His Lys Pro Gln Thr Thr Lys Pro Lys 85 90 95Glu
Val Pro Thr Thr Lys 10015306DNAArtificial SequenceRSV mutant
fragment 15cccacaacag tcaagactaa aaacacaaca acaacccaaa cacaacccag
caagcccact 60acaaaacaac gccaaaacaa accaccaaac aaacccaata atgattttca
cttcgaagtg 120tttaactttg taccctgcag catatgcagc aacaatccaa
cctgctgggc tatctgcgca 180agaataccaa acaaaaaacc aggaaagaaa
accaccacca agcctacaaa aaaaccaacc 240ttcaagacaa ccaaaaaaga
tcacaaacct caaaccacta aaccaaagga agtacccacc 300accaag
30616102PRTArtificial SequenceRSV mutant fragment 16Pro Thr Thr Val
Lys Thr Lys Asn Thr Thr Thr Thr Gln Thr Gln Pro 1 5 10 15Ser Lys
Pro Thr Thr Lys Gln Arg Gln Asn Lys Pro Pro Asn Lys Pro 20 25 30Asn
Asn Asp Phe His Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile 35 40
45Cys Ser Asn Asn Pro Thr Cys Trp Ala Ile Cys Ala Arg Ile Pro Asn
50 55 60Lys Lys Pro Gly Lys Lys Thr Thr Thr Lys Pro Thr Lys Lys Pro
Thr65 70 75 80Phe Lys Thr Thr Lys Lys Asp His Lys Pro Gln Thr Thr
Lys Pro Lys 85 90 95Glu Val Pro Thr Thr Lys 10017306DNAArtificial
SequenceRSV mutant fragment 17cccacaacag tcaagactaa aaacacaaca
acaacccaaa cacaacccag caagcccact 60acaaaacaac gccaaaacaa accaccaaac
aaacccaata atgattttca cttcgaagtg 120tttaactttg taccctgcag
catatgcagc aacaatccaa cctgctgggc tatctgcaaa 180agagcaccaa
acaaaaaacc aggaaagaaa accaccacca agcctacaaa aaaaccaacc
240ttcaagacaa ccaaaaaaga tcacaaacct caaaccacta aaccaaagga
agtacccacc 300accaag 30618102PRTArtificial SequenceRSV mutant
fragment 18Pro Thr Thr Val Lys Thr Lys Asn Thr Thr Thr Thr Gln Thr
Gln Pro 1 5 10 15Ser Lys Pro Thr Thr Lys Gln Arg Gln Asn Lys Pro
Pro Asn Lys Pro 20 25 30Asn Asn Asp Phe His Phe Glu Val Phe Asn Phe
Val Pro Cys Ser Ile 35 40 45Cys Ser Asn Asn Pro Thr Cys Trp Ala Ile
Cys Lys Arg Ala Pro Asn 50 55 60Lys Lys Pro Gly Lys Lys Thr Thr Thr
Lys Pro Thr Lys Lys Pro Thr65 70 75 80Phe Lys Thr Thr Lys Lys Asp
His Lys Pro Gln Thr Thr Lys Pro Lys 85 90 95Glu Val Pro Thr Thr Lys
10019306DNAArtificial SequenceRSV mutant fragment 19cccacaacag
tcaagactaa aaacacaaca acaacccaaa cacaacccag caagcccact 60acaaaacaac
gccaaaacaa accaccaaac aaacccaata atgattttca cttcgaagtg
120tttaactttg taccctgcag catatgcagc aacaatccaa cctgctgggc
tatctgcaaa 180agaataccaa acgcaaaacc aggaaagaaa accaccacca
agcctacaaa aaaaccaacc 240ttcaagacaa ccaaaaaaga tcacaaacct
caaaccacta aaccaaagga agtacccacc 300accaag 30620102PRTArtificial
SequenceRSV mutant fragment 20Pro Thr Thr Val Lys Thr Lys Asn Thr
Thr Thr Thr Gln Thr Gln Pro 1 5 10 15Ser Lys Pro Thr Thr Lys Gln
Arg Gln Asn Lys Pro Pro Asn Lys Pro 20 25 30Asn Asn Asp Phe His Phe
Glu Val Phe Asn Phe Val Pro Cys Ser Ile 35 40 45Cys Ser Asn Asn Pro
Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn 50 55 60Ala Lys Pro Gly
Lys Lys Thr Thr Thr Lys Pro Thr Lys Lys Pro Thr65 70 75 80Phe Lys
Thr Thr Lys Lys Asp His Lys Pro Gln Thr Thr Lys Pro Lys 85 90 95Glu
Val Pro Thr Thr Lys 10021306DNAArtificial SequenceRSV mutant
fragment 21cccacaacag tcaagactaa aaacacaaca acaacccaaa cacaacccag
caagcccact 60acaaaacaac gccaaaacaa accaccaaac aaacccaata atgattttca
cttcgaagtg 120tttaactttg taccctgcag catatgcagc aacaatccaa
cctgctgggc tatctgcaaa 180agaataccaa acaaagcacc aggaaagaaa
accaccacca agcctacaaa aaaaccaacc 240ttcaagacaa ccaaaaaaga
tcacaaacct caaaccacta aaccaaagga agtacccacc 300accaag
30622102PRTArtificial SequenceRSV mutant fragment 22Pro Thr Thr Val
Lys Thr Lys Asn Thr Thr Thr Thr Gln Thr Gln Pro 1 5 10 15Ser Lys
Pro Thr Thr Lys Gln Arg Gln Asn Lys Pro Pro Asn Lys Pro 20 25 30Asn
Asn Asp Phe His Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile 35 40
45Cys Ser Asn Asn Pro Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn
50 55 60Lys Ala Pro Gly Lys Lys Thr Thr Thr Lys Pro Thr Lys Lys Pro
Thr65 70
75 80Phe Lys Thr Thr Lys Lys Asp His Lys Pro Gln Thr Thr Lys Pro
Lys 85 90 95Glu Val Pro Thr Thr Lys 10023825DNAArtificial
SequenceRSV mutant fragment 23atg tcc gac aaa atc atc cac ctg act
gac gac agt ttt gac acg gat 48Met Ser Asp Lys Ile Ile His Leu Thr
Asp Asp Ser Phe Asp Thr Asp 1 5 10 15gta ctc aaa gcg gac ggg gcg
atc ctc gtc gat ttc tgg gca gag tgg 96Val Leu Lys Ala Asp Gly Ala
Ile Leu Val Asp Phe Trp Ala Glu Trp 20 25 30tgc ggt ccg tgc aaa atg
atc gcc ccg att ctg gat gaa atc gct gac 144Cys Gly Pro Cys Lys Met
Ile Ala Pro Ile Leu Asp Glu Ile Ala Asp 35 40 45gaa tat cag ggc aaa
ctg acc gtt gca aaa ctg aac atc gat caa aac 192Glu Tyr Gln Gly Lys
Leu Thr Val Ala Lys Leu Asn Ile Asp Gln Asn 50 55 60cct ggc act gcg
ccg aaa tat ggc atc cgt ggt atc ccg act ctg ctg 240Pro Gly Thr Ala
Pro Lys Tyr Gly Ile Arg Gly Ile Pro Thr Leu Leu 65 70 75 80ctg ttc
aaa aac ggt gaa gtg gcg gca acc aaa gtg ggt gca ctg tct 288Leu Phe
Lys Asn Gly Glu Val Ala Ala Thr Lys Val Gly Ala Leu Ser 85 90 95aaa
ggt cag ttg aaa gag ttc ctc gac gct aac ctg gcc ggt tct ggt 336Lys
Gly Gln Leu Lys Glu Phe Leu Asp Ala Asn Leu Ala Gly Ser Gly 100 105
110tct ggc cac atg cac cat cat cat cat cat tct tct ggt ctg gtg cca
384Ser Gly His Met His His His His His His Ser Ser Gly Leu Val Pro
115 120 125cgc ggt tct ggt atg aaa gaa acc gct gct gct aaa ttc gaa
cgc cag 432Arg Gly Ser Gly Met Lys Glu Thr Ala Ala Ala Lys Phe Glu
Arg Gln 130 135 140cac atg gac agc cca gat ctg ggt acc gat gac gac
gac aag acc ggg 480His Met Asp Ser Pro Asp Leu Gly Thr Asp Asp Asp
Asp Lys Thr Gly145 150 155 160ctt ctc ctc aac cat ggc gat atc gga
tcc gaa ttc ccc aca aca gtc 528Leu Leu Leu Asn His Gly Asp Ile Gly
Ser Glu Phe Pro Thr Thr Val 165 170 175aag act aaa aac aca aca aca
acc caa aca caa ccc agc aag ccc act 576Lys Thr Lys Asn Thr Thr Thr
Thr Gln Thr Gln Pro Ser Lys Pro Thr 180 185 190aca aaa caa cgc caa
aac aaa cca cca aac aaa ccc aat aat gat ttt 624Thr Lys Gln Arg Gln
Asn Lys Pro Pro Asn Lys Pro Asn Asn Asp Phe 195 200 205cac ttc gaa
gtg ttt aac ttt gta ccc tgc agc atc tgc agc aac aat 672His Phe Glu
Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn 210 215 220cca
acc tgc tgg gct atc tgc aaa aga ata cca aac aaa aaa cca gga 720Pro
Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro Gly225 230
235 240aag aaa acc acc acc aag cct aca aaa aaa cca acc ttc aag aca
acc 768Lys Lys Thr Thr Thr Lys Pro Thr Lys Lys Pro Thr Phe Lys Thr
Thr 245 250 255aaa aaa gat ctc aaa cct caa acc act aaa cca aag gaa
gta ccc acc 816Lys Lys Asp Leu Lys Pro Gln Thr Thr Lys Pro Lys Glu
Val Pro Thr 260 265 270acc aag tga 825Thr Lys *24274PRTArtificial
Sequence 24Met Ser Asp Lys Ile Ile His Leu Thr Asp Asp Ser Phe Asp
Thr Asp 1 5 10 15Val Leu Lys Ala Asp Gly Ala Ile Leu Val Asp Phe
Trp Ala Glu Trp 20 25 30Cys Gly Pro Cys Lys Met Ile Ala Pro Ile Leu
Asp Glu Ile Ala Asp 35 40 45Glu Tyr Gln Gly Lys Leu Thr Val Ala Lys
Leu Asn Ile Asp Gln Asn 50 55 60Pro Gly Thr Ala Pro Lys Tyr Gly Ile
Arg Gly Ile Pro Thr Leu Leu65 70 75 80Leu Phe Lys Asn Gly Glu Val
Ala Ala Thr Lys Val Gly Ala Leu Ser 85 90 95Lys Gly Gln Leu Lys Glu
Phe Leu Asp Ala Asn Leu Ala Gly Ser Gly 100 105 110Ser Gly His Met
His His His His His His Ser Ser Gly Leu Val Pro 115 120 125Arg Gly
Ser Gly Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln 130 135
140His Met Asp Ser Pro Asp Leu Gly Thr Asp Asp Asp Asp Lys Thr
Gly145 150 155 160Leu Leu Leu Asn His Gly Asp Ile Gly Ser Glu Phe
Pro Thr Thr Val 165 170 175Lys Thr Lys Asn Thr Thr Thr Thr Gln Thr
Gln Pro Ser Lys Pro Thr 180 185 190Thr Lys Gln Arg Gln Asn Lys Pro
Pro Asn Lys Pro Asn Asn Asp Phe 195 200 205His Phe Glu Val Phe Asn
Phe Val Pro Cys Ser Ile Cys Ser Asn Asn 210 215 220Pro Thr Cys Trp
Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro Gly225 230 235 240Lys
Lys Thr Thr Thr Lys Pro Thr Lys Lys Pro Thr Phe Lys Thr Thr 245 250
255Lys Lys Asp Leu Lys Pro Gln Thr Thr Lys Pro Lys Glu Val Pro Thr
260 265 270Thr Lys25825DNAArtificial SequenceRSV mutant fragment
25atg tcc gac aaa atc atc cac ctg act gac gac agt ttt gac acg gat
48Met Ser Asp Lys Ile Ile His Leu Thr Asp Asp Ser Phe Asp Thr Asp 1
5 10 15gta ctc aaa gcg gac ggg gcg atc ctc gtc gat ttc tgg gca gag
tgg 96Val Leu Lys Ala Asp Gly Ala Ile Leu Val Asp Phe Trp Ala Glu
Trp 20 25 30tgc ggt ccg tgc aaa atg atc gcc ccg att ctg gat gaa atc
gct gac 144Cys Gly Pro Cys Lys Met Ile Ala Pro Ile Leu Asp Glu Ile
Ala Asp 35 40 45gaa tat cag ggc aaa ctg acc gtt gca aaa ctg aac atc
gat caa aac 192Glu Tyr Gln Gly Lys Leu Thr Val Ala Lys Leu Asn Ile
Asp Gln Asn 50 55 60cct ggc act gcg ccg aaa tat ggc atc cgt ggt atc
ccg act ctg ctg 240Pro Gly Thr Ala Pro Lys Tyr Gly Ile Arg Gly Ile
Pro Thr Leu Leu 65 70 75 80ctg ttc aaa aac ggt gaa gtg gcg gca acc
aaa gtg ggt gca ctg tct 288Leu Phe Lys Asn Gly Glu Val Ala Ala Thr
Lys Val Gly Ala Leu Ser 85 90 95aaa ggt cag ttg aaa gag ttc ctc gac
gct aac ctg gcc ggt tct ggt 336Lys Gly Gln Leu Lys Glu Phe Leu Asp
Ala Asn Leu Ala Gly Ser Gly 100 105 110tct ggc cac atg cac cat cat
cat cat cat tct tct ggt ctg gtg cca 384Ser Gly His Met His His His
His His His Ser Ser Gly Leu Val Pro 115 120 125cgc ggt tct ggt atg
aaa gaa acc gct gct gct aaa ttc gaa cgc cag 432Arg Gly Ser Gly Met
Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln 130 135 140cac atg gac
agc cca gat ctg ggt acc gat gac gac gac aag acc ggg 480His Met Asp
Ser Pro Asp Leu Gly Thr Asp Asp Asp Asp Lys Thr Gly145 150 155
160ctt ctc ctc aac cat ggc gat atc gga tcc gaa ttc ccc aca aca gtc
528Leu Leu Leu Asn His Gly Asp Ile Gly Ser Glu Phe Pro Thr Thr Val
165 170 175aag act aaa aac aca aca aca acc caa aca caa ccc agc aag
ccc act 576Lys Thr Lys Asn Thr Thr Thr Thr Gln Thr Gln Pro Ser Lys
Pro Thr 180 185 190aca aaa caa cgc caa aac aaa cca cca aac aaa ccc
aat aat gat ttt 624Thr Lys Gln Arg Gln Asn Lys Pro Pro Asn Lys Pro
Asn Asn Asp Phe 195 200 205cac ttc gaa gtg ttt aac ttt gta ccc tgc
agc atc tgc agc aac aat 672His Phe Glu Val Phe Asn Phe Val Pro Cys
Ser Ile Cys Ser Asn Asn 210 215 220cca acc tgc tgg gct atc tgc aaa
aga ata cca gct aaa aaa cca gga 720Pro Thr Cys Trp Ala Ile Cys Lys
Arg Ile Pro Ala Lys Lys Pro Gly225 230 235 240aag aaa acc acc acc
aag cct aca aaa aaa cca acc ttc aag aca acc 768Lys Lys Thr Thr Thr
Lys Pro Thr Lys Lys Pro Thr Phe Lys Thr Thr 245 250 255aaa aaa gat
ctc aaa cct caa acc act aaa cca aag gaa gta ccc acc 816Lys Lys Asp
Leu Lys Pro Gln Thr Thr Lys Pro Lys Glu Val Pro Thr 260 265 270acc
aag tga 825Thr Lys *26274PRTArtificial Sequence 26Met Ser Asp Lys
Ile Ile His Leu Thr Asp Asp Ser Phe Asp Thr Asp 1 5 10 15Val Leu
Lys Ala Asp Gly Ala Ile Leu Val Asp Phe Trp Ala Glu Trp 20 25 30Cys
Gly Pro Cys Lys Met Ile Ala Pro Ile Leu Asp Glu Ile Ala Asp 35 40
45Glu Tyr Gln Gly Lys Leu Thr Val Ala Lys Leu Asn Ile Asp Gln Asn
50 55 60Pro Gly Thr Ala Pro Lys Tyr Gly Ile Arg Gly Ile Pro Thr Leu
Leu65 70 75 80Leu Phe Lys Asn Gly Glu Val Ala Ala Thr Lys Val Gly
Ala Leu Ser 85 90 95Lys Gly Gln Leu Lys Glu Phe Leu Asp Ala Asn Leu
Ala Gly Ser Gly 100 105 110Ser Gly His Met His His His His His His
Ser Ser Gly Leu Val Pro 115 120 125Arg Gly Ser Gly Met Lys Glu Thr
Ala Ala Ala Lys Phe Glu Arg Gln 130 135 140His Met Asp Ser Pro Asp
Leu Gly Thr Asp Asp Asp Asp Lys Thr Gly145 150 155 160Leu Leu Leu
Asn His Gly Asp Ile Gly Ser Glu Phe Pro Thr Thr Val 165 170 175Lys
Thr Lys Asn Thr Thr Thr Thr Gln Thr Gln Pro Ser Lys Pro Thr 180 185
190Thr Lys Gln Arg Gln Asn Lys Pro Pro Asn Lys Pro Asn Asn Asp Phe
195 200 205His Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser
Asn Asn 210 215 220Pro Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Ala
Lys Lys Pro Gly225 230 235 240Lys Lys Thr Thr Thr Lys Pro Thr Lys
Lys Pro Thr Phe Lys Thr Thr 245 250 255Lys Lys Asp Leu Lys Pro Gln
Thr Thr Lys Pro Lys Glu Val Pro Thr 260 265 270Thr
Lys27852DNAArtificial SequenceRSV mutant fragment 27atg ttc ctg ctg
gct gtt ttc tac ggt ggt tcc gac aaa atc atc cac 48Met Phe Leu Leu
Ala Val Phe Tyr Gly Gly Ser Asp Lys Ile Ile His 1 5 10 15ctg act
gac gac agt ttt gac acg gat gta ctc aaa gcg gac ggg gcg 96Leu Thr
Asp Asp Ser Phe Asp Thr Asp Val Leu Lys Ala Asp Gly Ala 20 25 30atc
ctc gtc gat ttc tgg gca gag tgg tgc ggt ccg tgc aaa atg atc 144Ile
Leu Val Asp Phe Trp Ala Glu Trp Cys Gly Pro Cys Lys Met Ile 35 40
45gcc ccg att ctg gat gaa atc gct gac gaa tat cag ggc aaa ctg acc
192Ala Pro Ile Leu Asp Glu Ile Ala Asp Glu Tyr Gln Gly Lys Leu Thr
50 55 60gtt gca aaa ctg aac atc gat caa aac cct ggc act gcg ccg aaa
tat 240Val Ala Lys Leu Asn Ile Asp Gln Asn Pro Gly Thr Ala Pro Lys
Tyr 65 70 75 80ggc atc cgt ggt atc ccg act ctg ctg ctg ttc aaa aac
ggt gaa gtg 288Gly Ile Arg Gly Ile Pro Thr Leu Leu Leu Phe Lys Asn
Gly Glu Val 85 90 95gcg gca acc aaa gtg ggt gca ctg tct aaa ggt cag
ttg aaa gag ttc 336Ala Ala Thr Lys Val Gly Ala Leu Ser Lys Gly Gln
Leu Lys Glu Phe 100 105 110ctc gac gct aac ctg gcc ggt tct ggt tct
ggc cac atg cac cat cat 384Leu Asp Ala Asn Leu Ala Gly Ser Gly Ser
Gly His Met His His His 115 120 125cat cat cat tct tct ggt ctg gtg
cca cgc ggt tct ggt atg aaa gaa 432His His His Ser Ser Gly Leu Val
Pro Arg Gly Ser Gly Met Lys Glu 130 135 140acc gct gct gct aaa ttc
gaa cgc cag cac atg gac agc cca gat ctg 480Thr Ala Ala Ala Lys Phe
Glu Arg Gln His Met Asp Ser Pro Asp Leu145 150 155 160ggt acc gat
gac gac gac aag acc ggg ctt ctc ctc aac cat ggc gat 528Gly Thr Asp
Asp Asp Asp Lys Thr Gly Leu Leu Leu Asn His Gly Asp 165 170 175atc
gga tcc gaa ttc ccc aca aca gtc aag act aaa aac aca aca aca 576Ile
Gly Ser Glu Phe Pro Thr Thr Val Lys Thr Lys Asn Thr Thr Thr 180 185
190acc caa aca caa ccc agc aag ccc act aca aaa caa cgc caa aac aaa
624Thr Gln Thr Gln Pro Ser Lys Pro Thr Thr Lys Gln Arg Gln Asn Lys
195 200 205cca cca aac aaa ccc aat aat gat ttt cac ttc gaa gtg ttt
aac ttt 672Pro Pro Asn Lys Pro Asn Asn Asp Phe His Phe Glu Val Phe
Asn Phe 210 215 220gta ccc tgc agc atc tgc agc aac aat cca acc tgc
tgg gct atc tgc 720Val Pro Cys Ser Ile Cys Ser Asn Asn Pro Thr Cys
Trp Ala Ile Cys225 230 235 240aaa aga ata cca aac aaa aaa cca gga
aag aaa acc acc acc aag cct 768Lys Arg Ile Pro Asn Lys Lys Pro Gly
Lys Lys Thr Thr Thr Lys Pro 245 250 255aca aaa aaa cca acc ttc aag
aca acc aaa aaa gat ctc aaa cct caa 816Thr Lys Lys Pro Thr Phe Lys
Thr Thr Lys Lys Asp Leu Lys Pro Gln 260 265 270acc act aaa cca aag
gaa gta ccc acc acc aag tga 852Thr Thr Lys Pro Lys Glu Val Pro Thr
Thr Lys * 275 28028283PRTArtificial Sequence 28Met Phe Leu Leu Ala
Val Phe Tyr Gly Gly Ser Asp Lys Ile Ile His 1 5 10 15Leu Thr Asp
Asp Ser Phe Asp Thr Asp Val Leu Lys Ala Asp Gly Ala 20 25 30Ile Leu
Val Asp Phe Trp Ala Glu Trp Cys Gly Pro Cys Lys Met Ile 35 40 45Ala
Pro Ile Leu Asp Glu Ile Ala Asp Glu Tyr Gln Gly Lys Leu Thr 50 55
60Val Ala Lys Leu Asn Ile Asp Gln Asn Pro Gly Thr Ala Pro Lys Tyr65
70 75 80Gly Ile Arg Gly Ile Pro Thr Leu Leu Leu Phe Lys Asn Gly Glu
Val 85 90 95Ala Ala Thr Lys Val Gly Ala Leu Ser Lys Gly Gln Leu Lys
Glu Phe 100 105 110Leu Asp Ala Asn Leu Ala Gly Ser Gly Ser Gly His
Met His His His 115 120 125His His His Ser Ser Gly Leu Val Pro Arg
Gly Ser Gly Met Lys Glu 130 135 140Thr Ala Ala Ala Lys Phe Glu Arg
Gln His Met Asp Ser Pro Asp Leu145 150 155 160Gly Thr Asp Asp Asp
Asp Lys Thr Gly Leu Leu Leu Asn His Gly Asp 165 170 175Ile Gly Ser
Glu Phe Pro Thr Thr Val Lys Thr Lys Asn Thr Thr Thr 180 185 190Thr
Gln Thr Gln Pro Ser Lys Pro Thr Thr Lys Gln Arg Gln Asn Lys 195 200
205Pro Pro Asn Lys Pro Asn Asn Asp Phe His Phe Glu Val Phe Asn Phe
210 215 220Val Pro Cys Ser Ile Cys Ser Asn Asn Pro Thr Cys Trp Ala
Ile Cys225 230 235 240Lys Arg Ile Pro Asn Lys Lys Pro Gly Lys Lys
Thr Thr Thr Lys Pro 245 250 255Thr Lys Lys Pro Thr Phe Lys Thr Thr
Lys Lys Asp Leu Lys Pro Gln 260 265 270Thr Thr Lys Pro Lys Glu Val
Pro Thr Thr Lys 275 28029852DNAArtificial SequenceRSV mutant
fragment 29atg ttc ctg ctg gct gtt ttc tac ggt ggt tcc gac aaa atc
atc cac 48Met Phe Leu Leu Ala Val Phe Tyr Gly Gly Ser Asp Lys Ile
Ile His 1 5 10 15ctg act gac gac agt ttt gac acg gat gta ctc aaa
gcg gac ggg gcg 96Leu Thr Asp Asp Ser Phe Asp Thr Asp Val Leu Lys
Ala Asp Gly Ala 20 25 30atc ctc gtc gat ttc tgg gca gag tgg tgc ggt
ccg tgc aaa atg atc 144Ile Leu Val Asp Phe Trp Ala Glu Trp Cys Gly
Pro Cys Lys Met Ile 35 40 45gcc ccg att ctg gat gaa atc gct gac gaa
tat cag ggc aaa ctg acc 192Ala Pro Ile Leu Asp Glu Ile Ala Asp Glu
Tyr Gln Gly Lys Leu Thr 50 55 60gtt gca aaa ctg aac atc gat caa aac
cct ggc act gcg ccg aaa tat 240Val Ala Lys Leu Asn Ile Asp Gln Asn
Pro Gly Thr Ala Pro Lys Tyr 65 70 75 80ggc atc cgt ggt atc ccg act
ctg ctg ctg ttc aaa aac ggt gaa gtg 288Gly Ile Arg Gly Ile Pro Thr
Leu Leu Leu Phe Lys Asn Gly Glu Val 85 90 95gcg gca acc aaa gtg ggt
gca ctg tct aaa ggt cag ttg aaa gag ttc 336Ala Ala Thr Lys Val Gly
Ala Leu Ser Lys Gly Gln Leu Lys Glu Phe 100 105 110ctc gac gct aac
ctg gcc ggt tct ggt tct ggc cac atg cac cat cat 384Leu Asp Ala Asn
Leu Ala Gly Ser Gly Ser Gly His Met His His His 115 120 125cat cat
cat tct tct ggt ctg gtg cca cgc ggt tct ggt atg aaa gaa 432His His
His Ser Ser Gly Leu Val Pro Arg Gly Ser Gly Met Lys Glu 130
135 140acc gct gct gct aaa ttc gaa cgc cag cac atg gac agc cca gat
ctg 480Thr Ala Ala Ala Lys Phe Glu Arg Gln His Met Asp Ser Pro Asp
Leu145 150 155 160ggt acc gat gac gac gac aag acc ggg ctt ctc ctc
aac cat ggc gat 528Gly Thr Asp Asp Asp Asp Lys Thr Gly Leu Leu Leu
Asn His Gly Asp 165 170 175atc gga tcc gaa ttc ccc aca aca gtc aag
act aaa aac aca aca aca 576Ile Gly Ser Glu Phe Pro Thr Thr Val Lys
Thr Lys Asn Thr Thr Thr 180 185 190acc caa aca caa ccc agc aag ccc
act aca aaa caa cgc caa aac aaa 624Thr Gln Thr Gln Pro Ser Lys Pro
Thr Thr Lys Gln Arg Gln Asn Lys 195 200 205cca cca aac aaa ccc aat
aat gat ttt cac ttc gaa gtg ttt aac ttt 672Pro Pro Asn Lys Pro Asn
Asn Asp Phe His Phe Glu Val Phe Asn Phe 210 215 220gta ccc tgc agc
atc tgc agc aac aat cca acc tgc tgg gct atc tgc 720Val Pro Cys Ser
Ile Cys Ser Asn Asn Pro Thr Cys Trp Ala Ile Cys225 230 235 240aaa
aga ata cca gct aaa aaa cca gga aag aaa acc acc acc aag cct 768Lys
Arg Ile Pro Ala Lys Lys Pro Gly Lys Lys Thr Thr Thr Lys Pro 245 250
255aca aaa aaa cca acc ttc aag aca acc aaa aaa gat ctc aaa cct caa
816Thr Lys Lys Pro Thr Phe Lys Thr Thr Lys Lys Asp Leu Lys Pro Gln
260 265 270acc act aaa cca aag gaa gta ccc acc acc aag tga 852Thr
Thr Lys Pro Lys Glu Val Pro Thr Thr Lys * 275 28030283PRTArtificial
Sequence 30Met Phe Leu Leu Ala Val Phe Tyr Gly Gly Ser Asp Lys Ile
Ile His 1 5 10 15Leu Thr Asp Asp Ser Phe Asp Thr Asp Val Leu Lys
Ala Asp Gly Ala 20 25 30Ile Leu Val Asp Phe Trp Ala Glu Trp Cys Gly
Pro Cys Lys Met Ile 35 40 45Ala Pro Ile Leu Asp Glu Ile Ala Asp Glu
Tyr Gln Gly Lys Leu Thr 50 55 60Val Ala Lys Leu Asn Ile Asp Gln Asn
Pro Gly Thr Ala Pro Lys Tyr65 70 75 80Gly Ile Arg Gly Ile Pro Thr
Leu Leu Leu Phe Lys Asn Gly Glu Val 85 90 95Ala Ala Thr Lys Val Gly
Ala Leu Ser Lys Gly Gln Leu Lys Glu Phe 100 105 110Leu Asp Ala Asn
Leu Ala Gly Ser Gly Ser Gly His Met His His His 115 120 125His His
His Ser Ser Gly Leu Val Pro Arg Gly Ser Gly Met Lys Glu 130 135
140Thr Ala Ala Ala Lys Phe Glu Arg Gln His Met Asp Ser Pro Asp
Leu145 150 155 160Gly Thr Asp Asp Asp Asp Lys Thr Gly Leu Leu Leu
Asn His Gly Asp 165 170 175Ile Gly Ser Glu Phe Pro Thr Thr Val Lys
Thr Lys Asn Thr Thr Thr 180 185 190Thr Gln Thr Gln Pro Ser Lys Pro
Thr Thr Lys Gln Arg Gln Asn Lys 195 200 205Pro Pro Asn Lys Pro Asn
Asn Asp Phe His Phe Glu Val Phe Asn Phe 210 215 220Val Pro Cys Ser
Ile Cys Ser Asn Asn Pro Thr Cys Trp Ala Ile Cys225 230 235 240Lys
Arg Ile Pro Ala Lys Lys Pro Gly Lys Lys Thr Thr Thr Lys Pro 245 250
255Thr Lys Lys Pro Thr Phe Lys Thr Thr Lys Lys Asp Leu Lys Pro Gln
260 265 270Thr Thr Lys Pro Lys Glu Val Pro Thr Thr Lys 275
28031852DNAArtificial SequenceRSV mutant fragment 31atg tcc gac aaa
atc atc cac ctg act gac gac agt ttt gac acg gat 48Met Ser Asp Lys
Ile Ile His Leu Thr Asp Asp Ser Phe Asp Thr Asp 1 5 10 15gta ctc
aaa gcg gac ggg gcg atc ctc gtc gat ttc tgg gca gag tgg 96Val Leu
Lys Ala Asp Gly Ala Ile Leu Val Asp Phe Trp Ala Glu Trp 20 25 30tgc
ggt ccg tgc aaa atg atc gcc ccg att ctg gat gaa atc gct gac 144Cys
Gly Pro Cys Lys Met Ile Ala Pro Ile Leu Asp Glu Ile Ala Asp 35 40
45gaa tat cag ggc aaa ctg acc gtt gca aaa ctg aac atc gat caa aac
192Glu Tyr Gln Gly Lys Leu Thr Val Ala Lys Leu Asn Ile Asp Gln Asn
50 55 60cct ggc act gcg ccg aaa tat ggc atc cgt ggt atc ccg act ctg
ctg 240Pro Gly Thr Ala Pro Lys Tyr Gly Ile Arg Gly Ile Pro Thr Leu
Leu 65 70 75 80ctg ttc aaa aac ggt gaa gtg gcg gca acc aaa gtg ggt
gca ctg tct 288Leu Phe Lys Asn Gly Glu Val Ala Ala Thr Lys Val Gly
Ala Leu Ser 85 90 95aaa ggt cag ttg aaa gag ttc ctc gac gct aac ctg
gcc ggt tct ggt 336Lys Gly Gln Leu Lys Glu Phe Leu Asp Ala Asn Leu
Ala Gly Ser Gly 100 105 110tct ggc cac atg cac cat cat cat cat cat
tct tct ggt ctg gtg cca 384Ser Gly His Met His His His His His His
Ser Ser Gly Leu Val Pro 115 120 125cgc ggt tct ggt atg aaa gaa acc
gct gct gct aaa ttc gaa cgc cag 432Arg Gly Ser Gly Met Lys Glu Thr
Ala Ala Ala Lys Phe Glu Arg Gln 130 135 140cac atg gac agc cca gat
ctg ggt acc gat gac gac gac aag acc ggg 480His Met Asp Ser Pro Asp
Leu Gly Thr Asp Asp Asp Asp Lys Thr Gly145 150 155 160ctt ctc ctc
aac cat ggc gat atc gga tcc gaa ttc ccc aca aca gtc 528Leu Leu Leu
Asn His Gly Asp Ile Gly Ser Glu Phe Pro Thr Thr Val 165 170 175aag
act aaa aac aca aca aca acc caa aca caa ccc agc aag ccc act 576Lys
Thr Lys Asn Thr Thr Thr Thr Gln Thr Gln Pro Ser Lys Pro Thr 180 185
190aca aaa caa cgc caa aac aaa cca cca aac aaa ccc aat aat gat ttt
624Thr Lys Gln Arg Gln Asn Lys Pro Pro Asn Lys Pro Asn Asn Asp Phe
195 200 205cac ttc gaa gtg ttt aac ttt gta ccc tgc agc atc tgc agc
aac aat 672His Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser
Asn Asn 210 215 220cca acc tgc tgg gct atc tgc aaa aga ata cca aac
aaa aaa cca gga 720Pro Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn
Lys Lys Pro Gly225 230 235 240aag aaa acc acc acc aag cct aca aaa
aaa cca acc ttc aag aca acc 768Lys Lys Thr Thr Thr Lys Pro Thr Lys
Lys Pro Thr Phe Lys Thr Thr 245 250 255aaa aaa gat ctc aaa cct caa
acc act aaa cca aag gaa gta ccc acc 816Lys Lys Asp Leu Lys Pro Gln
Thr Thr Lys Pro Lys Glu Val Pro Thr 260 265 270acc aag ggt ggt tac
ttc gtt gct ctg ctg ttc taa 852Thr Lys Gly Gly Tyr Phe Val Ala Leu
Leu Phe * 275 28032283PRTArtificial Sequence 32Met Ser Asp Lys Ile
Ile His Leu Thr Asp Asp Ser Phe Asp Thr Asp 1 5 10 15Val Leu Lys
Ala Asp Gly Ala Ile Leu Val Asp Phe Trp Ala Glu Trp 20 25 30Cys Gly
Pro Cys Lys Met Ile Ala Pro Ile Leu Asp Glu Ile Ala Asp 35 40 45Glu
Tyr Gln Gly Lys Leu Thr Val Ala Lys Leu Asn Ile Asp Gln Asn 50 55
60Pro Gly Thr Ala Pro Lys Tyr Gly Ile Arg Gly Ile Pro Thr Leu Leu65
70 75 80Leu Phe Lys Asn Gly Glu Val Ala Ala Thr Lys Val Gly Ala Leu
Ser 85 90 95Lys Gly Gln Leu Lys Glu Phe Leu Asp Ala Asn Leu Ala Gly
Ser Gly 100 105 110Ser Gly His Met His His His His His His Ser Ser
Gly Leu Val Pro 115 120 125Arg Gly Ser Gly Met Lys Glu Thr Ala Ala
Ala Lys Phe Glu Arg Gln 130 135 140His Met Asp Ser Pro Asp Leu Gly
Thr Asp Asp Asp Asp Lys Thr Gly145 150 155 160Leu Leu Leu Asn His
Gly Asp Ile Gly Ser Glu Phe Pro Thr Thr Val 165 170 175Lys Thr Lys
Asn Thr Thr Thr Thr Gln Thr Gln Pro Ser Lys Pro Thr 180 185 190Thr
Lys Gln Arg Gln Asn Lys Pro Pro Asn Lys Pro Asn Asn Asp Phe 195 200
205His Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn
210 215 220Pro Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys
Pro Gly225 230 235 240Lys Lys Thr Thr Thr Lys Pro Thr Lys Lys Pro
Thr Phe Lys Thr Thr 245 250 255Lys Lys Asp Leu Lys Pro Gln Thr Thr
Lys Pro Lys Glu Val Pro Thr 260 265 270Thr Lys Gly Gly Tyr Phe Val
Ala Leu Leu Phe 275 28033852DNAArtificial SequenceRSV mutant
fragment 33atg tcc gac aaa atc atc cac ctg act gac gac agt ttt gac
acg gat 48Met Ser Asp Lys Ile Ile His Leu Thr Asp Asp Ser Phe Asp
Thr Asp 1 5 10 15gta ctc aaa gcg gac ggg gcg atc ctc gtc gat ttc
tgg gca gag tgg 96Val Leu Lys Ala Asp Gly Ala Ile Leu Val Asp Phe
Trp Ala Glu Trp 20 25 30tgc ggt ccg tgc aaa atg atc gcc ccg att ctg
gat gaa atc gct gac 144Cys Gly Pro Cys Lys Met Ile Ala Pro Ile Leu
Asp Glu Ile Ala Asp 35 40 45gaa tat cag ggc aaa ctg acc gtt gca aaa
ctg aac atc gat caa aac 192Glu Tyr Gln Gly Lys Leu Thr Val Ala Lys
Leu Asn Ile Asp Gln Asn 50 55 60cct ggc act gcg ccg aaa tat ggc atc
cgt ggt atc ccg act ctg ctg 240Pro Gly Thr Ala Pro Lys Tyr Gly Ile
Arg Gly Ile Pro Thr Leu Leu 65 70 75 80ctg ttc aaa aac ggt gaa gtg
gcg gca acc aaa gtg ggt gca ctg tct 288Leu Phe Lys Asn Gly Glu Val
Ala Ala Thr Lys Val Gly Ala Leu Ser 85 90 95aaa ggt cag ttg aaa gag
ttc ctc gac gct aac ctg gcc ggt tct ggt 336Lys Gly Gln Leu Lys Glu
Phe Leu Asp Ala Asn Leu Ala Gly Ser Gly 100 105 110tct ggc cac atg
cac cat cat cat cat cat tct tct ggt ctg gtg cca 384Ser Gly His Met
His His His His His His Ser Ser Gly Leu Val Pro 115 120 125cgc ggt
tct ggt atg aaa gaa acc gct gct gct aaa ttc gaa cgc cag 432Arg Gly
Ser Gly Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln 130 135
140cac atg gac agc cca gat ctg ggt acc gat gac gac gac aag acc ggg
480His Met Asp Ser Pro Asp Leu Gly Thr Asp Asp Asp Asp Lys Thr
Gly145 150 155 160ctt ctc ctc aac cat ggc gat atc gga tcc gaa ttc
ccc aca aca gtc 528Leu Leu Leu Asn His Gly Asp Ile Gly Ser Glu Phe
Pro Thr Thr Val 165 170 175aag act aaa aac aca aca aca acc caa aca
caa ccc agc aag ccc act 576Lys Thr Lys Asn Thr Thr Thr Thr Gln Thr
Gln Pro Ser Lys Pro Thr 180 185 190aca aaa caa cgc caa aac aaa cca
cca aac aaa ccc aat aat gat ttt 624Thr Lys Gln Arg Gln Asn Lys Pro
Pro Asn Lys Pro Asn Asn Asp Phe 195 200 205cac ttc gaa gtg ttt aac
ttt gta ccc tgc agc atc tgc agc aac aat 672His Phe Glu Val Phe Asn
Phe Val Pro Cys Ser Ile Cys Ser Asn Asn 210 215 220cca acc tgc tgg
gct atc tgc aaa aga ata cca gct aaa aaa cca gga 720Pro Thr Cys Trp
Ala Ile Cys Lys Arg Ile Pro Ala Lys Lys Pro Gly225 230 235 240aag
aaa acc acc acc aag cct aca aaa aaa cca acc ttc aag aca acc 768Lys
Lys Thr Thr Thr Lys Pro Thr Lys Lys Pro Thr Phe Lys Thr Thr 245 250
255aaa aaa gat ctc aaa cct caa acc act aaa cca aag gaa gta ccc acc
816Lys Lys Asp Leu Lys Pro Gln Thr Thr Lys Pro Lys Glu Val Pro Thr
260 265 270acc aag ggt ggt tac ttc gtt gct ctg ctg ttc taa 852Thr
Lys Gly Gly Tyr Phe Val Ala Leu Leu Phe * 275 28034283PRTArtificial
Sequence 34Met Ser Asp Lys Ile Ile His Leu Thr Asp Asp Ser Phe Asp
Thr Asp 1 5 10 15Val Leu Lys Ala Asp Gly Ala Ile Leu Val Asp Phe
Trp Ala Glu Trp 20 25 30Cys Gly Pro Cys Lys Met Ile Ala Pro Ile Leu
Asp Glu Ile Ala Asp 35 40 45Glu Tyr Gln Gly Lys Leu Thr Val Ala Lys
Leu Asn Ile Asp Gln Asn 50 55 60Pro Gly Thr Ala Pro Lys Tyr Gly Ile
Arg Gly Ile Pro Thr Leu Leu65 70 75 80Leu Phe Lys Asn Gly Glu Val
Ala Ala Thr Lys Val Gly Ala Leu Ser 85 90 95Lys Gly Gln Leu Lys Glu
Phe Leu Asp Ala Asn Leu Ala Gly Ser Gly 100 105 110Ser Gly His Met
His His His His His His Ser Ser Gly Leu Val Pro 115 120 125Arg Gly
Ser Gly Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln 130 135
140His Met Asp Ser Pro Asp Leu Gly Thr Asp Asp Asp Asp Lys Thr
Gly145 150 155 160Leu Leu Leu Asn His Gly Asp Ile Gly Ser Glu Phe
Pro Thr Thr Val 165 170 175Lys Thr Lys Asn Thr Thr Thr Thr Gln Thr
Gln Pro Ser Lys Pro Thr 180 185 190Thr Lys Gln Arg Gln Asn Lys Pro
Pro Asn Lys Pro Asn Asn Asp Phe 195 200 205His Phe Glu Val Phe Asn
Phe Val Pro Cys Ser Ile Cys Ser Asn Asn 210 215 220Pro Thr Cys Trp
Ala Ile Cys Lys Arg Ile Pro Ala Lys Lys Pro Gly225 230 235 240Lys
Lys Thr Thr Thr Lys Pro Thr Lys Lys Pro Thr Phe Lys Thr Thr 245 250
255Lys Lys Asp Leu Lys Pro Gln Thr Thr Lys Pro Lys Glu Val Pro Thr
260 265 270Thr Lys Gly Gly Tyr Phe Val Ala Leu Leu Phe 275
2803510PRTArtificial SequenceHydrophobic anchor 35Met Phe Leu Leu
Ala Val Phe Tyr Gly Gly 1 5 10369PRTArtificial SequenceHydrophobic
anchor 36Gly Gly Tyr Phe Val Ala Leu Leu Phe 1 53743DNAArtificial
SequencePrimer for the G128-229, I185A mutant 37cctgctgggc
tgcctgcaaa agaataccaa acaaaaaacc agg 433843DNAArtificial
SequencePrimer for the G128-229, I185A mutant 38cctggttttt
tgtttggtat tcttttgcag gcagcccagc agg 433942DNAArtificial
SequencePrimer for the G128-229, C186A mutant 39ctgctgggct
atcgccaaaa gaataccaaa caaaaaacca gg 424042DNAArtificial
SequencePrimer for the G128-229, C186A mutant 40cctggttttt
tgtttggtat tcttttggcg atagcccagc ag 424142DNAArtificial
SequencePrimer for the G128-229, K187A mutant 41ctgctgggct
atctgcgcaa gaataccaaa caaaaaacca gg 424242DNAArtificial
SequencePrimer for the G128-229, K187A mutant 42cctggttttt
tgtttggtat tcttgcgcag atagcccagc ag 424342DNAArtificial
SequencePrimer for the G128-229, R188A mutant 43ctgctgggct
atctgcaaag caataccaaa caaaaaacca gg 424442DNAArtificial
SequencePrimer for the G128-229, R188A mutant 44cctggttttt
tgtttggtat tgctttgcag atagcccagc ag 424542DNAArtificial
SequencePrimer for the G128-229, I189A mutant 45ctgctgggct
atctgcaaaa gagcaccaaa caaaaaacca gg 424642DNAArtificial
SequencePrimer for the G128-229, I189A mutant 46cctggttttt
tgtttggtgc tcttttgcag atagcccagc ag 424742DNAArtificial
SequencePrimer for the G128-229, P190A mutant 47ctgctgggct
atctgcaaaa gaatagcaaa caaaaaacca gg 424842DNAArtificial
SequencePrimer for the G128-229, P190A mutant 48cctggttttt
tgtttgctat tcttttgcag atagcccagc ag 424943DNAArtificial
SequencePrimer for the G128-229, N191A mutant 49ctgcaaaaga
ataccagcca aaaaaccagg aaagaaaacc acc 435043DNAArtificial
SequencePrimer for the G128-229, N191A mutant 50ggtggttttc
tttcctggtt ttttggctgg tattcttttg cag 435143DNAArtificial
SequencePrimer for the G128-229, K192A mutant 51ctgggctatc
tgcaaaagaa taccaaacgc aaaaccagga aag 435243DNAArtificial
SequencePrimer for the G128-229, K192A mutant 52ctttcctggt
tttgcgtttg gtattctttt gcagatagcc cag 435343DNAArtificial
SequencePrimer for the G128-229, K193A mutant 53gcaaaagaat
accaaacaaa gcaccaggaa agaaaaccac cac 435443DNAArtificial
SequencePrimer for the G128-229, K193A mutant 54gtggtggttt
tctttcctgg tgctttgttt ggtattcttt tgc 4355306DNAArtificial
SequenceRSV mutant fragment 55cccacaacag tcaagactaa aaacacaaca
acaacccaaa cacaacccag caagcccact 60acaaaacaac gccaaaacaa accaccaaac
aaacccaata atgattttca cttcgaagtg 120tttaactttg taccctgcag
catatgcagc aacaatccaa cctgctgggc tatctgcaaa 180agaatagcag
ccaaaaaacc aggaaagaaa accaccacca agcctacaaa aaaaccaacc
240ttcaagacaa ccaaaaaaga tcacaaacct caaaccacta aaccaaagga
agtacccacc 300accaag 30656102PRTArtificial SequenceRSV mutant
fragment 56Pro Thr Thr Val Lys Thr Lys Asn Thr Thr Thr
Thr Gln Thr Gln Pro 1 5 10 15Ser Lys Pro Thr Thr Lys Gln Arg Gln
Asn Lys Pro Pro Asn Lys Pro 20 25 30Asn Asn Asp Phe His Phe Glu Val
Phe Asn Phe Val Pro Cys Ser Ile 35 40 45Cys Ser Asn Asn Pro Thr Cys
Trp Ala Ile Cys Lys Arg Ile Ala Ala 50 55 60Lys Lys Pro Gly Lys Lys
Thr Thr Thr Lys Pro Thr Lys Lys Pro Thr65 70 75 80Phe Lys Thr Thr
Lys Lys Asp His Lys Pro Gln Thr Thr Lys Pro Lys 85 90 95Glu Val Pro
Thr Thr Lys 10057306DNAArtificial SequenceRSV mutant fragment
57cccacaacag tcaagactaa aaacacaaca acaacccaaa cacaacccag caagcccact
60acaaaacaac gccaaaacaa accaccaaac aaacccaata atgattttca cttcgaagtg
120tttaactttg taccctgcag catatgcagc aacaatccaa cctgctgggc
tatctgcaaa 180gcaataccag ccaaaaaacc aggaaagaaa accaccacca
agcctacaaa aaaaccaacc 240ttcaagacaa ccaaaaaaga tcacaaacct
caaaccacta aaccaaagga agtacccacc 300accaag 30658102PRTArtificial
SequenceRSV mutant fragment 58Pro Thr Thr Val Lys Thr Lys Asn Thr
Thr Thr Thr Gln Thr Gln Pro 1 5 10 15Ser Lys Pro Thr Thr Lys Gln
Arg Gln Asn Lys Pro Pro Asn Lys Pro 20 25 30Asn Asn Asp Phe His Phe
Glu Val Phe Asn Phe Val Pro Cys Ser Ile 35 40 45Cys Ser Asn Asn Pro
Thr Cys Trp Ala Ile Cys Lys Ala Ile Pro Ala 50 55 60Lys Lys Pro Gly
Lys Lys Thr Thr Thr Lys Pro Thr Lys Lys Pro Thr65 70 75 80Phe Lys
Thr Thr Lys Lys Asp His Lys Pro Gln Thr Thr Lys Pro Lys 85 90 95Glu
Val Pro Thr Thr Lys 10059306DNAArtificial SequenceRSV mutant
fragment 59cccacaacag tcaagactaa aaacacaaca acaacccaaa cacaacccag
caagcccact 60acaaaacaac gccaaaacaa accaccaaac aaacccaata atgattttca
cttcgaagtg 120tttaactttg taccctgcag catatgcagc gccaatccaa
cctgctgggc tatctgcaaa 180agaataccaa acaaaaaacc aggaaagaaa
accaccacca agcctacaaa aaaaccaacc 240ttcaagacaa ccaaaaaaga
tcacaaacct caaaccacta aaccaaagga agtacccacc 300accaag
30660102PRTArtificial SequenceRSV mutant fragment 60Pro Thr Thr Val
Lys Thr Lys Asn Thr Thr Thr Thr Gln Thr Gln Pro 1 5 10 15Ser Lys
Pro Thr Thr Lys Gln Arg Gln Asn Lys Pro Pro Asn Lys Pro 20 25 30Asn
Asn Asp Phe His Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile 35 40
45Cys Ser Ala Asn Pro Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn
50 55 60Lys Lys Pro Gly Lys Lys Thr Thr Thr Lys Pro Thr Lys Lys Pro
Thr65 70 75 80Phe Lys Thr Thr Lys Lys Asp His Lys Pro Gln Thr Thr
Lys Pro Lys 85 90 95Glu Val Pro Thr Thr Lys 10061306DNAArtificial
SequenceRSV mutant fragment 61cccacaacag tcaagactaa aaacacaaca
acaacccaaa cacaacccag caagcccact 60acaaaacaac gccaaaacaa accaccaaac
aaacccaata atgattttca cttcgaagtg 120tttaactttg taccctgcag
catatgcagc aacgctccaa cctgctgggc tatctgcaaa 180agaataccaa
acaaaaaacc aggaaagaaa accaccacca agcctacaaa aaaaccaacc
240ttcaagacaa ccaaaaaaga tcacaaacct caaaccacta aaccaaagga
agtacccacc 300accaag 30662102PRTArtificial SequenceRSV mutant
fragment 62Pro Thr Thr Val Lys Thr Lys Asn Thr Thr Thr Thr Gln Thr
Gln Pro 1 5 10 15Ser Lys Pro Thr Thr Lys Gln Arg Gln Asn Lys Pro
Pro Asn Lys Pro 20 25 30Asn Asn Asp Phe His Phe Glu Val Phe Asn Phe
Val Pro Cys Ser Ile 35 40 45Cys Ser Asn Ala Pro Thr Cys Trp Ala Ile
Cys Lys Arg Ile Pro Asn 50 55 60Lys Lys Pro Gly Lys Lys Thr Thr Thr
Lys Pro Thr Lys Lys Pro Thr65 70 75 80Phe Lys Thr Thr Lys Lys Asp
His Lys Pro Gln Thr Thr Lys Pro Lys 85 90 95Glu Val Pro Thr Thr Lys
10063306DNAArtificial SequenceRSV mutant fragment 63cccacaacag
tcaagactaa aaacacaaca acaacccaaa cacaacccag caagcccact 60acaaaacaac
gccaaaacaa accaccaaac aaacccaata atgattttca cttcgaagtg
120tttaactttg taccctgcag catatgcagc aacaatccaa cctgctgggc
tatctgcaaa 180agaataccaa acaaaaaacc aggagcgaaa accaccacca
agcctacaaa aaaaccaacc 240ttcaagacaa ccaaaaaaga tcacaaacct
caaaccacta aaccaaagga agtacccacc 300accaag 30664102PRTArtificial
SequenceRSV mutant fragment 64Pro Thr Thr Val Lys Thr Lys Asn Thr
Thr Thr Thr Gln Thr Gln Pro 1 5 10 15Ser Lys Pro Thr Thr Lys Gln
Arg Gln Asn Lys Pro Pro Asn Lys Pro 20 25 30Asn Asn Asp Phe His Phe
Glu Val Phe Asn Phe Val Pro Cys Ser Ile 35 40 45Cys Ser Asn Asn Pro
Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn 50 55 60Lys Lys Pro Gly
Ala Lys Thr Thr Thr Lys Pro Thr Lys Lys Pro Thr65 70 75 80Phe Lys
Thr Thr Lys Lys Asp His Lys Pro Gln Thr Thr Lys Pro Lys 85 90 95Glu
Val Pro Thr Thr Lys 10065306DNAArtificial SequenceRSV mutant
fragment 65cccacaacag tcaagactaa aaacacaaca acaacccaaa cacaacccag
caagcccact 60acaaaacaac gccaaaacaa accaccaaac aaacccaata atgattttca
cttcgaagtg 120tttaactttg taccctgcag catatgcagc aacaatccaa
cctgctgggc tatctgcaaa 180agaataccaa acaaaaaacc aggaaaggca
accaccacca agcctacaaa aaaaccaacc 240ttcaagacaa ccaaaaaaga
tcacaaacct caaaccacta aaccaaagga agtacccacc 300accaag
30666102PRTArtificial SequenceRSV mutant fragment 66Pro Thr Thr Val
Lys Thr Lys Asn Thr Thr Thr Thr Gln Thr Gln Pro 1 5 10 15Ser Lys
Pro Thr Thr Lys Gln Arg Gln Asn Lys Pro Pro Asn Lys Pro 20 25 30Asn
Asn Asp Phe His Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile 35 40
45Cys Ser Asn Asn Pro Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn
50 55 60Lys Lys Pro Gly Lys Ala Thr Thr Thr Lys Pro Thr Lys Lys Pro
Thr65 70 75 80Phe Lys Thr Thr Lys Lys Asp His Lys Pro Gln Thr Thr
Lys Pro Lys 85 90 95Glu Val Pro Thr Thr Lys 10067306DNAArtificial
SequenceRSV mutant fragment 67cccacaacag tcaagactaa aaacacaaca
acaacccaaa cacaacccag caagcccact 60acaaaacaac gccaaaacaa accaccaaac
aaacccaata atgattttca cttcgaagtg 120tttaactttg taccctgcag
catatgcagc aacaatccaa cctgctgggc tatctgcaaa 180agaataccaa
acaaaaaacc aggaaagaaa accaccacca agcctacagc aaaaccaacc
240ttcaagacaa ccaaaaaaga tcacaaacct caaaccacta aaccaaagga
agtacccacc 300accaag 30668102PRTArtificial SequenceRSV mutant
fragment 68Pro Thr Thr Val Lys Thr Lys Asn Thr Thr Thr Thr Gln Thr
Gln Pro 1 5 10 15Ser Lys Pro Thr Thr Lys Gln Arg Gln Asn Lys Pro
Pro Asn Lys Pro 20 25 30Asn Asn Asp Phe His Phe Glu Val Phe Asn Phe
Val Pro Cys Ser Ile 35 40 45Cys Ser Asn Asn Pro Thr Cys Trp Ala Ile
Cys Lys Arg Ile Pro Asn 50 55 60Lys Lys Pro Gly Lys Lys Thr Thr Thr
Lys Pro Thr Ala Lys Pro Thr65 70 75 80Phe Lys Thr Thr Lys Lys Asp
His Lys Pro Gln Thr Thr Lys Pro Lys 85 90 95Glu Val Pro Thr Thr Lys
10069306DNAArtificial SequenceRSV mutant fragment 69cccacaacag
tcaagactaa aaacacaaca acaacccaaa cacaacccag caagcccact 60acaaaacaac
gccaaaacaa accaccaaac aaacccaata atgattttca cttcgaagtg
120tttaactttg taccctgcag catatgcagc aacaatccaa cctgctgggc
tatctgcaaa 180agaataccaa acaaaaaacc aggaaagaaa accaccacca
agcctacaaa agcaccaacc 240ttcaagacaa ccaaaaaaga tcacaaacct
caaaccacta aaccaaagga agtacccacc 300accaag 30670102PRTArtificial
SequenceRSV Mutant Fragment 70Pro Thr Thr Val Lys Thr Lys Asn Thr
Thr Thr Thr Gln Thr Gln Pro 1 5 10 15Ser Lys Pro Thr Thr Lys Gln
Arg Gln Asn Lys Pro Pro Asn Lys Pro 20 25 30Asn Asn Asp Phe His Phe
Glu Val Phe Asn Phe Val Pro Cys Ser Ile 35 40 45Cys Ser Asn Asn Pro
Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn 50 55 60Lys Lys Pro Gly
Lys Lys Thr Thr Thr Lys Pro Thr Lys Ala Pro Thr65 70 75 80Phe Lys
Thr Thr Lys Lys Asp His Lys Pro Gln Thr Thr Lys Pro Lys 85 90 95Glu
Val Pro Thr Thr Lys 100718PRTArtificial SequenceEpitope Tag 71Asp
Tyr Lys Asp Asp Asp Asp Lys 1 5728PRTArtificial SequenceEpitope Tag
72Asp Leu Tyr Asp Asp Asp Asp Lys 1 5
* * * * *
References